VOLUME 31 · GENERAL INDEX

ABATZI TH-A. *See* KISS A, **259**
Abdominal ultrasound, intraoperative *(Leading article)*, **368**
Acetate absorption in normal and secreting rat jejunum, **170**
Achalasia, oesophageal, postganglionic nerve stimulation in: in vitro study, **17**
ACHARYA SK. *See* ARORA A, **1419**
Acid reflux and cigarette smoking, **4**
Acidification, oesophageal, and lower oesophageal sphincter pressure, **266**
Acid (itу) *See also* Gastric; Intragastric
Acrodermatitis enteropathica with normal zinc concentrations *(Letter)*, **243**
Acyclovir in prevention of duodenal ulcer recurrence, **151**
Adenocarcinoma cell line HT 29 in human colon, laminin binding proteins in cell membranes of, **70**
stomal, in Crohn's disease *(Case report)*, **1329**
Adenoma, colorectal, gastrointestinal intraluminal pH in, **1355**
liver cell, systemic AA amyloidosis induced by *Case report)*, **361**
villous, of the common hepatic duct: role of ultrasound in management, *(Case report)*, **558**
Adenomas, colonic, and colorectal cancer, low diacylglycerol values in, **1041**
Adenovirus, human, serotype 12, synthetic dodecapeptide derived from: cellular hypersensitivity in coeliac disease, **668**
ADLER G. *See* MUNDLOS S, **1324**
Agalactosyl IgG in inflammatory bowel disease: correlation with C-reactive protein, **431**
AGAPE D. *See* VECCHI M, **482**
AGUAYO JL. *See* PARRILLA P, **964**
AHLBERG J. *See* SAHLIN S, **100**
AHLBOM A. *See* PERSSON P-G, **1377**
AIDS, Epstein-Barr virus associated oesophageal ulcers in, **1223**
AISO S. *See* HIBI T, **1371**
AKAMA H: A case of nodular regenerative hyperplasia of the liver, CREST syndrome, and primary biliary cirrhosis *(Letter)*, **1335**
AKKERMANS LMA. *See* SCHAAP HM, **984**
Alanine and glucose transport enhanced in cystic fibrosis, **817**
ALBERT V, YOUNG GP, MORTON CL, ROBINSON P, BHATHAL PS: Systemic factors are trophic in bypassed rat small intestine in the absence of luminal contents, **311**, *(Letter)*, **959**
Albumin infusion, intravenous, for hyponatraemia in cirrhotic patients with ascites, **204**, *(Letter)*, **1419**
Alcohol dehydrogenase activity, hepatic, in alcoholics with and without liver disease, **707**
fed rats, protein synthesis of muscle fractions from small intestine in, **305**
pure, injection of, and heat probe thermocoagulation in massive peptic ulcer haemorrhage, trial of, **753**
Alcoholic liver disease, glutathione S-transferases in, **909**
liver disease, lipid peroxidation and hepatic antioxidants in, **1311**
Aldosterone in regulation of colonic sodium transport in early childhood, **194**
ALEOTTI A. *See* CASELLI M, **1423**
ALEXANDER-WILLIAMS J. *See* MOREL P, **875**
ALEXIOU A. *See* ARCHIMANDRITIS AJ, **481**
AL KARAWI MA. *See* MOHAMED ARE, **439**
ALLEMANN P. *See* MERKI HS, **148**
ALLISON C. *See* GINBSON GR, **679**
ALMDAL T, HEINDORFF H, BARDRAM L, VILSTRUP H: Increased amino acid clearance and urea synthesis in a patient with glucagonoma, **946**
ALMDAL T. *See* RASMUSSEN TN, **92**
ALVISI V. *See* CASELLI M, **1423**, PAZZI P, **1422**
Amino acids, clearance of, and urea synthesis, increased in a patient with glucagonoma *(Case report)*, **946**
acids, decrease in plasma concentrations induced by caerulein: test of pancreatic function, **926**
5-Aminosalicylic acid in ulcerative colitis, therapeutic action of, **184**
acid, disposition by olsalazine and mesalazine in patients with ulcerative colitis, **1271**
acid, olsalazine, and sulphasalazine, scavenger effect of *(Letter)*, **730**
acid treatment: effect on in vitro natural killer cell activity, **1030**
Amyloidosis, AA, systemic, induced by liver cell adenoma *(Case report)*, **361**
Anaemia, obscure, and hepatic dysfunction in Castleman's disease *(Case report)*, **834**,
See also Pernicious anaemia
Anaerobic bacterial culture supernatant, enteric, and deoxycholate, effects on intestinal calcium absorption and disaccharidase activity, **770**
Anal function and rectal sensation in patients with faecal incontinence, **1056**
ANAND BS. *See* MISRA SP, **1073**
ANDERBERG B. *See* ROLNY P, **821**
——: *See* GJORUP I, **1411**
ANDERSEN JR. *See* HEGNHOJ J, **1076**
——: *See* MURRAY AW, **270**
ANDERSSON K-E. *See* TOTTRUP A, **17**
ANGELIN B. *See* BERGLUND L, **899**
ANISS AM. *See* WEGMAN EA, **1289**
Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects, **458**
physiologic function and faecal incontinence, efficacy of biofeedback training in improving, **1395**
Antibiotics, adjuvant, in duodenal ulcers treated with bismuth subcitrate, **999**
Anticolon antibody production in vitro by mucosal or peripheral blood lymphocytes from patients with ulcerative colitis, **1371**
Antigliadin antibody and jejunal Ig secretion in adult coeliac disease, **1345**
ANTONI M. *See* BOURLIERE M, **949**
Antroduodenal motility, interdigestive, in dyspeptic patients improved by longterm oral cisapride, **286**
APARICIO-PAGES MN, VERSPAGET HW, HAFKENSCHEID JCM, CRAMA-BOHBOUTH GE, PENA AS, WETERMAN IT, LAMERS CBH: Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity, **1030**
Aphthous ulcer patients: effector cells responsible for in vitro cytotoxicity of blood leucocytes for oral epithelial cells, **294**
APPELMAN HD: Cancer in an ileoanal reservoir *(Letter)*, **1161**
Appendix, goblet cell, carcinoid of, **322**, *(Letter)*, **840**
ARATO A. *See* VERKASALO MA, **422**
ARCHIMANDRITIS AJ, TJIVRAS M, DAVARIS P, ALEXIOU A, BITSIKAS J: Helicobacter associated gastritis in patients with duodenal ulcer: the influence of various drugs *(Letter)*, **481**
ARMBRECHT U, STOCKBRUGGER RW, RODE J, MENON GG, COTTON PB: Development of gastric dysplasia in pernicious anaemia: a clinical and endoscopic follow up study of 80 patients, **1105**
ARNDORFER RC. *See* HELM JF, **266**
ARNOUX D. *See* BOURLIERE M, **949**
ARORA A, ACHARYA SK Prediction of severity of acute pancreatitis *(Letter)*, **1419**
Arterial oxygen saturation during upper gastrointestinal endoscopy: effects of a midazolam/pethidine combination, **270**
Arteritis, mesenteric, **956**
Takayasu's, associated with idiopathic ulcerative colitis *(Case report)*, **831**
ARVILL A. *See* ROLNY P, **821**
Ascites, intravenous albumin infusion for hyponatraemia in cirrhotic patients with, **204**
ASHRAF M. *See* DOWSETT JF, **905**
Aspirin induced gastric mucosal injury in man abolished by omeprazole, **514**
ASQUITH P. *See* MIKE N, **883**
Asthma and gastro-oesophageal reflux *(Leading article)*, **1**
ATKINSON M. *See* OLIVER SE, **750**
Autoimmune involvement in the pathogenesis of inflammatory bowel diseases *(Leading article)*, **961**
Avery Jones, Sir Francis, at 80 *(Birthday tribute)*, **489**
Awards, **732**
AXELSON J. *See* TIELEMANS Y, **274**
AXON ATR. *See* CRABTREE JE, **1033**; HESSEY SJ, **134**; LANSDOWN M, **977**
AYRES RCS, ROBERTSON DAF, DEWBURY KC, MILLWARD-SADLER GH, SMITH CL: Spontaneous regression of hepatocellular carcinoma, **722**

BABBS C. *See* MCMAHON RFT, **484**
Bacteria, adhesion of, and disease activity in Helicobacter associated chronic gastritis, **134**
tightly spiral shaped, in the human stomach: another cause of active chronic gastritis?, **139**
Bacterial invasion of Peyer's patches, involvement of M cells in, **1011**
overgrowth, jejunal, and intestinal permeability in children with immunodeficiency syndromes, **879**
See also Anaerobic bacterial culture
BAGG J. *See* THOMAS DW, **294**
BAGNOLO F. *See* TESTONI PA, **286**
BAKER R. *See* MARSH MN, **32**
BALLESTRERO A. *See* DALLEGRI F, **184**
Balloon catheter, designed for angioplasty, modified for use in the dilatation of tight biliary strictures, **565**
BANERJEE AK: Systemic factors and luminal contents in gut adaptation *(Letter)*, **959**
——, PETERS TJ: Experimental non-steroidal anti- inflammatory drug-induced enteropathy in the rat: similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors, **1358**
Bangladesh, acute diarrhoea in expatriates in *(Letter)*, **123**
BARBARA L. *See* BOLONDI L, **1306**; GIONCHETTI P, **730**; GULLO L, **926**
BARDHAN KD, MORRIS P, THOMPSON M, DHANDE DS, HINCHLIFFE RFC, JONES RB, DALY MJ, CARROLL NJH: Omeprazole in the treatment of erosive oesophagitis refractory to high dose cimetidine and ranitidine, **745**
BARDRAM L. *See* ALMDAL TP, **946**
BARON JH, KARIM QN, WALKER MM: *H pylori* and duodenal ulcer *(Letter)*, **242**

——: *See* JACYNA MR, **714**
——: short biography of, **1084**
BARR H, KRASNER N, RAOUF A, WALKER RJ: Prospective randomised trial of laser therapy only and laser therapy followed by endoscopic intubation for the palliation of malignant dysphagia, **252**, *(Letter)*, **1161**
BARRESI G, TUCCARI G, TEDESCHI A, MAGAZZU G: Lectin binding sites in the jujunal mucosa of patients with gluten sensitive enteropathy *(Letter)*, **482**
Barrett's oesophagus, evaluation of the magnitude of gastro-oesophageal reflux in, **964**
BARRY JL. *See* CLOAREC D, **300**
BARTON JR, RIAD MA, GAZE MN, MARAN AGD, FERGUSON A: Mucosal immunodeficiency in smokers, and in patients with epithelial head and neck tumours, **378**
——: *See also* O'MAHONY S, **1341**
BASSETT KS. *See* BATE CM, **968**
BATE CM: Randomised, double blind comparison of omeprazole and cimetidine in the treatment of symptomatic gastric ulcer *(Reply to letter)*, **483**
——, KEELING PWN, O'MORAIN C, WILKINSON SP, FOSTER DN, MOUNTFORD RA, TEMPERLEY JM, HARVEY RF, THOMPSON DG, DAVIS M, FORGACS IC, BASSETT KS, RICHARDSON PDI: Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations, **968**
BATENBURG PL. *See* DEES A, **1414**
BATMAN PA, KAPEMBWA MS, GRIFFIN GE: Enteropathy associated with HIV *(Letter)*, **960**
Batteries *See* Button batteries
BAUMANN W. *See* KELLER KM, **1156**
BAXTER P, GOLDHILL J, HARDCASTLE J, HARDCASTLE PT, TAYLOR CJ: Enhanced intestinal glucose and alanine transport in cystic fibrosis, **817**
BAYLISS AP. *See* FEATHERSTONE K, **834**
BEARDSHALL K. *See* FREEMAN H, **1318**
BECKER S. *See* SINGER MV, **1335**
BEGER HG. *See* SCHOENBERG MH, **1138**
Belching controlled by the lower oesophageal sphincter, **639**
BELL J. *See* STEADMAN C, **845**
BELLAMY D. *See* HINSULL SM, **389**
BELLUZI A. *See* GIOCHETTI P, **730**
BENDTSEN F. *See* RUNE SJ, **151**
BENNETT JR. *See* GOLDMAN JM, **1**
BENSI G. *See* DOBRILLA G, **355**
BENVENISTE J. *See* DENIZOT Y, **1242**
BERANEK JT: Osler's disease is not a telangiectasia but a tumour *(Letter)*, **242**
BERGLUND L, ANGELIN B, HULTCRANTZ R, EINARSSON K, EMTESTAM L, DRUMMOND G, KAPPAS A: Studies with the haeme oxygenase inhibitor Sn-protoporphyrin in patients with primary biliary cirrhosis and idiopathic haemochromatosis, **899**
BERGMANN H. *See* KISS A, **259**
BERNARD JP. *See* SARLES H, **629**
BERNERSEN B, JOHNSEN R, STRAUME B, BURHOL PG, JENSSEN TG, STAKKEVOLD PA: Towards a true prevalence of peptic ulcer: the Sorreisa gastrointestinal disorder study, **989**
BETHGE H. *See* BLUM AL, **825**
BHASIN DK. *See* KOCHHAR R, **334**; SAKHUJA V, **831**
BHASKAR NK. *See* DANESHMEND TK, **514**
BHATHAL PS. *See* ALBERT V, **311**
BIANCHI PORRO G, PARENTE F, SANGALETTI O: Inhibition of nocturnal acidity is important but not essential for duodenal ulcer healing, **397**
——: *See also* PACE F, **1025**
Bicarbonate secretion in rat duodenum and human stomach in vivo, effect of bismuth subcitrate and sucralfate on, **26**, *(Letter)*, **958**
BIEMOND I. *See* WETERMAN IT, **1387**
BIJMA AM. *see* VAN DER HAM AC, **807**
Bile acid synthesis and biliary lipid composition in familial hypercholesterolaemia, effect of pravastatin on, **348**
and mucosa of gall bladder, interactions between; relevance to gall stone formation *(Progress report)*, **568**
duct antibodies crossreacting with blood group antigens in primary sclerosing cholangitis, **698**
duct, common, stenosis of: pathology in cystic fibrosis *(Case report)*, **236**
duct obstruction, incidence of conditions leading to, and requirements for diagnostic and therapeutic biliary procedures, **1150**
duct stones, extra-and intrahepatic: fragmentation by electromagnetically generated extracorporeal shockwaves, **222**
duct *See also* Hepatic duct
from gall bladder, and endoscopically obtained from duodenum, comparison of, **1407**
Biliary access: needle knife papillotomy, **905**
cirrhosis, primary, lung lavage cells from, immunological features may reflect those in pulmonary sarcoidosis, **208**
cirrhosis, primary, low molecular weight IgM in, **88**
cirrhosis, primary, haeme oxygenase inhibitor Sn-protoporphyrin in, **899**
cirrhosis, primary, nodular regenerative hyperplasia of the liver, and CREST syndrome (Letters), **483**, **1335**
cirrhosis, primary, referral of patients for liver transplantation, **1069**
endoprostheses, clogging of, **913**
lipid composition and bile acid synthesis in familial hypercholesterolaemia, effect of pravastatin on, **348**
lipid secretion, hepatic, and gall bladder biliary lipid mass in gall stone patients: effect of ursodeoxycholic acid, **226**
motility *(Progress report)*, **571**
strictures, tight, use of a modified angioplasty balloon catheter in the dilatation of, **565**
Billroth II gastric remnant, myoelectrical activity of, **984**
BILTON D, FOX R, WEBB AK, LAWLER W, MCMAHON RFT, HOWAT JMT: Pathology of common bile duct stenosis in cystic fibrosis, **236**
BINNIE NR, KAWIMBE BM, PAPACHRYSOSTOMOU M, SMITH AN: Use of the pudendo-anal reflex in the treatment of neurogenic faecal incontinence, **1051**
Biofeedback training in improving faecal incontinence and anorectal physiologic function, efficacy of, **1395**
Biopsies *See* Fine needle
BIRD SP, HEWITT D, RATCLIFFE B, GURR MI: Effects of lactulose and lactitol on protein digestion and metabolism in conventional and germ free animal models: relevance of the results to their use in the treatment of portosystemic encephalopathy, **1403**
BISHOP AE. *See* COUPE M, **144**
Bismuth induced encephalopathy caused by tripotassium dicitrato bismuthate in a patient with chronic renal failure *(Case report)*, **359**, *(Letter)*, **1086**
subcitrate, adjuvant antibiotic therapy in duodenal ulcers treated with, **999**
subcitrate and sucralfate, effect on rat duodenal and human gastric bicarbonate secretion in vivo, **26**, *(Letter)*, **958**
subcitrate, effect on symptoms and gastric histology in non-ulcer dyspepsia, *(Clinical trial)*, **476**
subcitrate, repeated, effect on the response of rat gastric mucosa to presence of luminal ethanol, **389**
subsalicylate reduces peptic injury of oesophagus in rabbits, **11**
BITSIKAS J. *See* ARCHIMANDRITIS AJ, **481**
BJARNASON I, HOPKINSON N, ZANELLI G, PROUSE P, SMETHURST P, GUMPEL JM, LEVI AJ: Treatment of non-steroidal-anti- inflammatory drug induced enteropathy, **777**
——: *See also* MARSH MN, **32**; SMITH T, **1120**; TEAHON K, **1133**
BJERGLUND ANDERSEN L. *See* HEGNHOJ J, **1076**
BLACKETT RL. *See* PRIMROSE JN, **763**
BLAKE H. *See* RAO KJM, **565**
BLAKE JC, SAWYERR AM, DOOLEY JS, SCHEUER PJ, MCINTYRE N: Severe hepatitis caused by cyproterone acetate *(Case report)*, **556**
BLESSING K. *See* PARK K, **322**, **840**
Blood group antigens in primary sclerosing cholangitis, bile duct antibodies crossreacting with, **698**
leucocytes from aphthous ulcer patients: effector cells responsible for in vitro cytotoxicity for oral epithelial cells, **294**
BLUM AL, BETHGE H, BODE JCH, DOMSCHKE W, FEURLE G, HACKENBERG K, HAMMER B, HUTTEMANN W, JUNG M, KACHEL G, KAESS H, MANDOLD BC, PETER P, PFLEIDERER T, ROHNER HG, RASENACK U, SANWALD R, STALDER GA, VALLOTTON J-J: Sucralfate in the treatment and prevention of gastric ulcer: multicentre double blind placebo controlled study, **825**
BOCCIERI A. *See* CUCCHIARA S, **21**, **129**
BODE JCH. *See* BLUM AL, **825**
BOERBOOMS AMT. *See* VAN KLAVEREN RJ, **953**
BOGENTOFT C. *See* BROWN NJ, **1126**
BOGLIOLO F. *See* DALLEGRI F, **184**
BOLONDI L, GAIANI S, LI BASSI S, ZIRONI G, CASANOVA P, BARBARA L: Effect of secretin on portal venous flow, **1306**
BONNEVIE O. *See* RUNE SJ, **151**
Book reviews:
BAILLIERES *Clinical gastroenterology* ed by IAD Bouchier, *Vol 3 Jaundice*, 1989, **485**
BARKIN JS, ROGERS AI, eds: *Difficult decisions in digestive diseases*, 1989, **587**
BEATTIE AD: *Diagnostic tests in gastroenterology*, 1989, **732**
BLASER MJ, ed: *Campylobacter pylori in gastritis and peptic ulcer disease*, 1989, **587**
COLLINS *Reference dictionary: medical quotations*, ed by J Dainth, A Isaacs, 1990, **1338**
COTTON PB, TYTGAT GNJ, WILLIAMS CB: *Annual of gastrointestinal endoscopy*, 1989, **1337**
DAVISON JS: *Gastrointestinal secretion*, 1989, **485**
European Journal of Gastroenterology and Hepatology. Vol 1, no 1, ed by JJ Misiewicz, 1989, **586**
FISCHER JE: *Common problems in gastrointestinal surgery*. Vol 1, 1989, **585**
GARNER A, WHITTLE BJR, eds: *Advances in drug therapy of gastrointestinal ulceration*, 1989, **732**
GITNICK G, ed: *Current gastroenterology*. Vol 9, 1989, **586**
——: ed: *Current hepatology*. Vol 9, 1989, **587**
GRANT THOMPSON W: *Gut reactions: understanding symptoms of the digestive tract*, 1990, **1336**
GROTH CG: *Pancreatic transplantation*, 1988, **1337**
HENNESSEY TPJ, CUSCHIERI A, BENNETT JR: *Reflux oesophagitis*, 1989, **1336**
ITOH Z: *Motilin*, 1990, **1337**

LEVINE MS: *Radiology of the esophagus*, 1989, 588
MCDERMOTT WV, ed: *Surgery of the liver*, 1989, 586
MARSTON A, BULKLEY GF, FIDDIAN-GREEN RG, *et al*: *Splanchnic ischaemia and multiple organ failure*, 1989, 731
MOYER MP, POSTE GH: *Colon cancer cells*, 1990, 1336
PAUMGARTNER G, STIEHL A, GEROK E, eds: *Trends in bile acid research, Falk Symposium 52*, 1989, 588
PEPPERCORN MA: *Therapy of inflammatory bowel disease: new . . . approaches*, 1990, 731
POYNARD T, PIGNON JP, eds: *Duodenal ulcer . . . clinical trials*, 1989, 586
PREECE PE, CUSCHIERI A, ROSIN RD: *Cancer of the bile ducts and pancreas*, 1989, 1336
RATHBONE BJ, HEATLEY RV, eds: *Campylobacter pylori and gastroduodenal disease*, 1989, 485
READ NW, ed: *Gastrointestinal motility: which test?* 1989, 732
SHEARMAN DJC, FINLAYSON N, CARTER DC, eds: *Diseases of the gastrointestinal tract and liver*, 1989, 586
SHERLOCK S: *Diseases of the liver and biliary system*. 8th ed, 1989, 485
SODEMAN WA, SALADIN TA, BOYD WP: *Geriatric gastroenterology*, 1989, 1338
TANNER S: *Paediatric hepatology*, 1989, 587
VAN NESS MV, GURNEY MS, eds: *Handbook of gastrointestinal drug therapy*, 1989, 587
WATTS G: *Irritable bowel syndrome: a practical guide*, 1990, 1336
WILLIAMSON RCN, COOPER MJ, eds: *Emergency abdominal surgery*, 1989, 1337
Books received, 588
BOOTH C: Sir FA Jones at 80, 490
BOOTH IW. *See* KELLER KM, 1156
BORDIGONI L. *See* BOURLIERE M, 949
BORNET F. *See* CLOAREC D, 300
BORODO MM. *See* WATSON AJM, 170
BOTTA D. *See* BOURLIERE M, 949
BOTTOMLEY JM. *See* JONES RH, 401
BOUDJELAL M. *See* FIEVET P, 361
BOUHNIK Y. *See* FLOURIE B, 684
BOULOS PB. *See* LOIZOU LA, 812
BOURLIERE M, LE TREUT YP, ARNOUX D, CASTELLANI P, BORDIGONI L, MAILLOT A, ANTONI M, BOTTA D, POL B, GAUTHIER AP: Acute Budd-Chiari syndrome with hepatic failure and obstruction of the inferior vena cava as presenting manifestations of hereditary protein C deficiency, 949
Bowel disease, granulomatous, animal model, effect of immune modulating agents, 674
Bowel *See also* Inflammatory bowel; Intestinal; Intestine; Irritable bowel; Short bowel
BOWN SG. *See* LOIZOU LA, 812
BOYD EJS. *See* FULLARTON GM, 518
BOYLSTON AW. *See* KITCHEN VS, 1223
BRANDTZAEG P. *See* VALNES K, 647
BRANSKI D. *See* LIGUMSKY M, 1416
BREALEY R. *See* DUBE R, 431
Breath tests *See* ^{13}C-urea; Carbon dioxide; Cholesteryl octanoate; Hydrogen
BRIGNOLA C. *See* GIOCHETTI P, 730
British Digestive Foundation, service to the media *(Letter)*, 731
British Society of Gastroenterology early gastric cancer/dysplasia survey: an interim report, 115
Society of Gastroenterology, Presidents of, 1084
BRITTON DC. *See* HOLMAN RAE, 504
BROCCHI E. *See* CORAZZA GR, 1080
BROOKE B: Sir FA Jones at 80, 489
BROOME U, GLAUMANN H, HULTCRANTZ R: Liver histology and follow up of 68 patients with ulcerative colitis and normal liver function tests, 468
BROUET P. *See* CALES P, 1298
BROWN ML. *See* KAMATH PS, 443
BROWN NJ, READ NW, RICHARDSON A, RUMSEY RDE, BOGENTOFT C: Characterisitics of lipid substances activating the ileal brake in the rat, 1126
BROWN SR, CANN PA, READ NW: Effect of coffee on distal colon function, 450
BRUNT PW. *See* FEATHERSTONE T, 834
Brush border *See* Jejunal brush border
BRYNSKOV J, TVEDE N: Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin, 795
BUCHLER M. *See* SCHOENBERG MH, 1138
BUCKELS JAC. *See* NEUBERGER JM, 1069
Budd-Chiari syndrome, acute, with hepatic failure and inferior vena caval obstruction: presentation of hereditary protein C deficiency *(Case report)*, 949
BUDILLON G. *See* PIGNATA C, 879
BUKHAVE K. *See* STAERK LAURSEN L, 1271
Bulimia nervosa and a stepped care approach to management *(Leading article)*, 1220
nervosa, oesophageal and gastric motor activity in, 259
BULLIMORE DW. *See* CRABTREE JE, 1033
BULTMANN B. *See* SCHOENBERG MH, 1138
BURCHARTH F. *See* GJORUP I, 1411
BURHOL PG. *See* BERNERSEN B, 989
BURROUGHS AK. *See* MCCORMICK PA, 204, 561
BUSCARINI E. *See* SBOLLI G, 1303
BUSCARINI L. *See* SBOLLI G, 1303
Button batteries, swallowed, management, 867
BUURMAN WA. *See* GREVE JW, 198

^{13}C-urea breath test in the detection of *H pylori* and in monitoring effect of tripotassium dicitratobismuthate in non-ulcer dyspepsia, 1237
CADRANEL JF, GRIPPON P, GARGOT D, OPOLON P: CREST syndrome: nodular regenerative hyperplasia of the liver and primary biliary cirrhosis an overlap syndrome? *(Letter)*, 483
Caecal and faecal homogenates, hydrogen and methane production in the human colon compared in, 684
Caerulein induced plasma amino acid decrease: test of pancreatic function, 926
CAFFREY C, HITMAN GA, NIVEN MJ, CASSELL PG, KUMAR P, FRY L, MACKINTOSH P, GALLAGHER R, FEIGHERY C, WEIR D, SACHS JA: HLA-DP and coeliac disease: family and population studies, 663
CALAM J. *See* COUPE M, 144; FREEMAN TC, 1318; PLAYFORD RJ, 359
Calcium *See* Intestinal calcium
CALDOW JL. *See* JONES RH, 401
CALES P, DESMORAT H, VINEL JP, CAUCANAS JP, RAVAUD A, GERIN P, BROUET P, PASCAL JP: Incidence of large oesophageal varices in patients with cirrhosis: application to prophylaxis of first bleeding, 1298
CALETTI G. *See* CORAZZA GR, 1080
CAMERLINGO F. *See* CUCCHIARA S, 21
Camostate (FOY-305) improves the therapeutic effect of peritoneal lavage on taurocholate induced pancreatitis, 934
CAMPBELL A. *See* FULLARTON GM, 231
CAMPBELL CA. *See* COLSON DJ, 370
CAMPBELL MJ. *See* PLAYFORD RJ, 359
CAMPIERI M. *See* GIONCHETTI P, 730
Campylobacter pylori See Helicobacter pylori
Cancer and precancer in extensive ulcerative colitis: findings among 401 patients over 22 years, 800
colorectal, low diacylglycerol values in, 1041
gastric, early, survey of British Society of Gastroenterology: interim report, 115
gastric, gastric emptying in, 767
in an ileoanal reservoir: a new late complication? *(Case report)*, 473, *(Letter)*, 1161
oesophageal, squamous cell, inoperable, what does radiotherapy add to survival over endoscopic intubation alone?, 750
of the pancreas *(Leading article)*, 494
rectosigmoid, endoscopic Nd:YAG laser treatment of, 812
See also Carcinoma
Candida albicans, antibody in Crohn's disease, 536
CANN PA. *See* BROWN SR, 450
CAPOZZI C. *See* CUCCHIARA S, 21
CAPRON JP. *See* FIEVET P, 361
CAPUTO E. *See* MELA GS, 1087
Carbenoxolone *See* Pyrogastrone
Carbohydrate malabsorption, lactulose H_2 breath tests for quantifying, interval sampling of end-expiratory H_2 concentrations, 37
Carbohydrates, refined, intake of, and duodenal ulcer: case-control study, 993
^{13}Carbon dioxide breath test to measure hydrolysis of various starch formulations in healthy subjects, 175
Carcinoid, goblet cell, of the appendix, 322, *(Letter)*, 840
tumour of the common bile duct complicating von Hippel-Lindau syndrome *(Case report)*, 728
Carcinoma and dysplasia in ulcerative colitis, diagnosis of, microspectrophotometric DNA analysis, 1266
colorectal, gastrointestinal intraluminal pH in, 1355
gastric stump: risks and pathogenesis *(Leading article)*, 1217
hepatocellular, diagnosis of, ultrasound guided fine needle aspiration biopsy, 1303
hepatocellular, spontaneous regression of *(Case report)*, 722
oesophageal, in Sri Lanka *(Letter)*, 242
pancreatic, with polyarthritis, fat necrosis, and high serum lipase and trypsin activity, 953
squamous, in the liver *(Case report)*, 1333
See also Adenocarcinoma; Cancer
Caroli's disease, epithelial dysplasia in *(Letter)*, 584
CARROLL NJH. *See* BARDHAN KD, 745; DAHN TCB, 509
CARTER DC: Cancer of the pancreas *(Leading article)*, 494
CASANOVA P. *See* BOLONDI L, 1306
CASELLI M, MORSIANI E, ALEOTTI A, ALVISI V: Gall bladder epithelium and cholesterol gall stones, *(Letter)*, 1423
CASPARY W. *See* HELLSTERN A, 922
CASSELL PG. *See* CAFFREY C, 663
CASTELLANI P. *See* BOURLIERE M, 949
Castleman's disease, obscure anaemia and hepatic dysfunction in *(Case report)*, 834
Cathepsins D and E in gastric tissue: an immunohistochemical study, 1250
Catheter *See* Balloon catheter
CAUCANAS JP. *See* CALES P, 1298
CAVANNA L. *See* SBOLLI G, 1303

CD25 cells *See* Interleukin-2 receptor
Cefixime, suppression of *H pylori* by, reduction of gastric ulcer recurrence after, **973**
Cell membranes of a human colon adenocarcinoma cell line, identification of laminin binding proteins in, **70**
CELLE G. *See* SAVARINO V, **364**, **584**
Cellular procoagulant activity in gastroenterology *(Progress report)*, **239**
CHACKO A, SZAZ KF, HOWARD J, CUMMINGS JH: Non-invasive method for delivery of tracer substances or small quantities of other materials to the colon, **106**
CHADEE K, NDARATHI C, KELLER K: Binding of proteolytically-degraded human colonic mucin glycoproteins to the Gal/GalNAc adherence lectin of *Entamoeba histolytica*, **890**
CHAN-WILDE C. *See* KANG JY, **550**
CHAPARALA RC. *See* TAY HP, **11**
CHARNLEY RM, HARDCASTLE JD: Intraoperative abdominal ultrasound *(Leading article)*, **368**
CHAWLA YK, DILAWARI JB, RAMESH GN, KAUR U, MITRA SK, WALIA BNS: Sclerotherapy in extrahepatic portal venous obstruction, **213**
CHENG J. *See* COENE PPL, **913**
CHESNER I. *See* HANNAN A, **1246**
Chest pain: nutcracker, neurosis, or sampling bias? *(Leading article)*, **736**
pain of oesophageal origin, diagnosis of, ambulatory 24 hour intra-oesophageal pH and pressure recordings *v* provocation tests, **738**
CHESTA J, DEBNAM ES, SRAI SKS, EPSTEIN O: Delayed stomach to caecum transit time in the diabetic rat. Possible role of hyperglucagonaemia, **660**
CHETTY U. *See* PARK K, **322**, **840**
CHEW R. *See* KANG JY, **550**
Cholangitis, primary sclerosing, bile duct antibodies crossreacting with blood group antigens in, **698**
Cholecystectomy, morphine induced pain and rises in liver enzymes after: sympathetic activation? **217**
Cholecystokinin *See* Enteroendocrine cells
Cholelithiasis *See* Gall stone
Cholera toxin, secretory response to, and fluid absorption, in the rat, modulation by dietary fat, **1256**
Cholestasis, chronic, in cystic fibrosis: effects of ursodeoxycholic acid on nutrition and liver function, **918**
Cholestatic jaundice, chronic liver disease and tumour necrosis factor *(Hypothesis)*, **938**
Cholesteryl octanoate breath test: monitoring enzyme replacement treatment in exocrine pancreatic insufficiency, **1324**
Cholinergic neuroeffector transmission of ganglionic and aganglionic colon in Hirschsprung's disease, **1046**
CHOONG HL. *See* WEE A, **1093**
CHOUDHARY V. *See* MISRA SP, **1073**
CHOY MY, WALKER-SMITH JA, WILLIAMS CB, MACDONALD TT: Differential expression of CD25 (interleukin-2 receptor) on lamina propria T cells and macrophages in the intestinal lesions in Crohn's disease and ulcerative colitis, **1365**
CHRISTENSEN KC. *See* LADEFOGED K, **124**
CHRONOS N. *See* MCCORMICK PA, **561**
CHUGH KS. *See* SAKHUJA V, **831**
CICCIMARRA F. *See* PIGNATA C, **879**
Cigarette smoking *See* Smoking
Cimetidine and omeprazole in reflux oesophagitis, comparison of, **968**
and omeprazole in symptomatic gastric ulcer, comparison of, *(Letter)*, **483**
and omeprazole in symptomatic erosive reflux oesophagitis, double blind comparison of, **509**
and pyrogastrone in reflux oesophagitis *(Clinical trial)*, **351**
high dose and ranitidine, omeprazole in erosive oesophagitis refractory to, **745**
predictors of duodenal ulcer healing during treatment with, **758**
Cimetropium bromide in longterm treatment of irritable bowel syndrome *(Clinical trial)*, **355**
Cirrhosis, biliary *See* Biliary cirrhosis
incidence of large oesophageal varices in patients with, **1298**
of the liver, nodular regenerative hyperplasia mimicking, **725**
Cirrhotic patients with ascites, intravenous albumin infusion for hyponatraemia in, **204**, *(Letter)*, **1419**
Cisapride, effects on oesophageal motility and acid reflux in infants with gastro-oesophageal reflux disease, **21**
oral, longterm, improves interdigestive antroduodenal motility in dyspeptic patients, **286**
CIVARDI G. *See* SBOLLI G, **1303**
CLAMP SE. *See* UNWIN BJ, **115**
CLARKE PD. *See* RAMAGE JK, **123**
CLARKE SW. *See* SPITERI MA, **208**
CLEMENTS D, NEWMAN P, ETHERINGTON R, LAWRIE BW, RHODES J: Squamous carcinoma in the liver, **1333**
CLOAREC D, BORNET F, GOUILLOUD S, BARRY JL, SALIM B, GALMICHE JP: Breath hydrogen response to lactulose in healthy subjects: relationship to methane producing status, **300**
Clostridium difficile, enterotoxins from; diarrhoeogenic potency and morphological effects in the rat intestine, **781**
COATES GC. *See* ROBERTS-THOMSON IC, **217**
Coeliac disease, activated eosinophils in *(Letter)*, **583**
disease, adult, jejunal Ig and antigliadin antibody secretion in, **1345**
disease and HLA-DP: family and population studies, **663**
disease: cellular hypersensitivity to a synthetic dodecapeptide derived from human adenovirus 12, **668**
disease, effect of diet and age on jejunal and circulating lymphocyte subsets in children with, **422**
disease, HLA status, mucosal morphology, permeability and epithelial lymphocyte populations in first degree relatives of patients with, **32**
disease, molecular basis of *(Leading article)*, **497**
disease, non-responsive, small bowel enema in, **883**
disease, partial lipodystrophy in *(Case report)*, **717**
disease, signs of increased leakage over jejunal mucosa during gliadin challenge in, **153**
disease, unsuspected, loss of duodenal folds allows diagnosis, *(Case report)*, **1080**
ganglionectomy *(Letter)*, **1335**
COENE PPLO, GROEN AK, CHENG J, OUT MMJ, TYTGAT GNJ, HUIBREGTSE K: Clogging of biliary endoprostheses: a new perspective, **913**
Coffee, effect on distal colon function, **450**
COHEN Z. *See* STERN H, **473**; WAKEFIELD A, **239**
Colectomy rate in ulcerative colitis: epidemiologic study, **329**
COLGAN SM. *See* PRIOR A, **896**
COLIN-JONES DG. *See* DEHN TCB, **509**; GEAR MWL, **1150**
Colitis and colonic mucus *(Letter)*, **730**
experimental, role of reactive oxygen metabolites in, **786**
granulomatous, in a rat model: progression of chronic inflammatory lesions reduced by dietary fish oil, **539**
See also Ulcerative colitis
COLLEY JRT. *See* GEAR MWL, **1150**
COLLINS JSA, HAMILTON PW, WATT PCH, SLOAN JM, LOVE AHG: Quantitative histological study of mucosal inflammatory cell densities in endoscopic duodenal biopsy specimens from dyspeptic patients using computer linked image analysis, **858**
COLLINS JV. *See* HANSON PJV, **657**
COLOMBEL JF, JANIN A, TORPIER G: Activated eosinophils in coeliac disease *(Letter)*, **583**
——, MASCART-LEMONE F, NEMETH J, VAERMAN JP, DIVE C, RAMBAUD JC: Jejunal immunoglobulin and antigliadin antibody secretion in adult coeliac disease, **1345**
Colon adenocarcinoma, human, cell line HT 29, identification of laminin binding proteins in cell membranes of, **70**
adenomas and colorectal cancer, low diacylglycerol values in, **1041**
anastomosis, healing, and peritoneal macrophages in the rat, eicosanoid profile of, **807**
distal, effect of coffee on function of, **450**
ganglionic and aganglionic in Hirschsprung's disease, cholinergic neuroeffector transmission in, **1046**
human, alternative pathways for hydrogen disposal during fermentation, **679**
human, functioning, 15-N-urea metabolism in, **454**
non-invasive method for delivery of tracer substances or other materials to, **106**
proximal and distal, of guinea pig, potassium concentration at the mucosal surface of, **64**
Colonic capacitance and transit in man: modulation by luminal contents and drugs, **443**
disease, schistosomal, **439**
extract, human, enriched with a 40kDa protein, circulating antibodies against, in ulcerative colitis, **1016**
mucin glycoproteins, proteolytically-degraded, human, binding to the Gal/GalNAc adherence lectin of *Entamoeba histolytica*, **890**
mucus and colitis *(Letter)*, **730**
myoelectrical signals recorded with intramuscular electrodes in the human rectosigmoid in vivo, concordance between, **1289**
resistance arteries, isolated, short chain fatty acids dilate, **1391**
sodium transport: development in early childhood and regulation by aldosterone, **194**
Colorectal adenoma or carcinoma, gastrointestinal intraluminal pH in, **1355**
cancer and colonic adenomas, low diacylglycerol values in, **1041**
cancer in ulcerative colitis, screening for *(Leading article)*, 1089
neoplasia, role of gastrointestinal investigations in a screening study, **1294**
COLSON DJ, CAMPBELL CA, WRIGHT VA, WATSON BW: Predictive value of oesophageal pH variables in children with gastro-oesophageal reflux, **370**
Computerised pump to maintain constant intragastric pH, **1246**
Computed tomography and endoscopy in the management of alimentary tract lipomas *(Case report)*, **550**
CONNOLLY GM, FORBES A, GAZZARD BG: Investigation of seemingly pathogen-negative diarrhoea in patients infected with HIV1, **886**
Constipation, chronic, intractable, motor neuropathy and reduced filling of the rectum in, **1284**
COOPERATIVE STUDY GROUP: Double blind comparative study of omeprazole and ranitidine in patients with duodenal or gastric ulcer: a multicentre trial, **653**
CORAL A. *See* JENNINGS PE, **558**
CORAZZA GR, BROCCHI E, CALETTI G, GASBARRINI G: Loss of duodenal folds allows diagnosis of unsuspected coeliac disease *(Case report)*, **1080**

COTTING J, LENTZE MJ, REICHEN J: Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis, **918**
COTTON PB. *See* ARMBRECHT U, **1105**
COUDRAY-LUCAS C. *See* ZIEGLER F, **1277**
COUPE M, REES H, SPRINGER CJ, BISHOP AE, MORRIS JA, POLAK JM, CALAM J: Gastric enterochromaffin-like cells in hypergastrinaemic duodenal ulcer disease, **144**
CRABTREE JE, JUBY LD, HEATLEY RV, LOBO AJ, BULLIMORE DW, AXON ATR: Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity, **1033**
CRAMA-BOHBOUTH GE. *See* APARICIO-PAGES MN, **1030**
CRAMPTON JR. *See* SHORROCK CJ, **26**, **958**
CREAN GP. *See* FULLARTON GM, **518**
CREST syndrome, nodular regenerative hyperplasia of the liver and primary biliary cirrhosis, an overlap syndrome? *(Letters)*, **483**, **1335**
CREUTZFELDT W. *See* LEONHARDT U, **934**
CRICHTON S. *See* O'MAHONY S, **1341**
CRIMMINS F. *See* STEADMAN C, **845**
Crohn's disease and ulcerative colitis, differential expression of CD25 (interleukin-2 receptor) on lamina propria T cells and macrophages in intestinal lesions in, **1365**
disease, antibody to selected strains of *Saccharomyces cerevisiae* and *Candida albicans* in, **536**
disease, elemental diet in, ten years' experience, **1133**
disease, elemental diet, use by gastroenterologists *Letter)*, **1424**
disease, ileal, glucocorticoids in, **325**
disease in the city of Derby 1951-85, **1262**
disease, mortality and causes of death, 50 years' experience in Leiden University Hospital, **1387**
disease, pancreatic function in, **1076**
disease, plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with, **795**
disease, rectal mucosal dysplasia in, **1382**
disease, soluble interleukin-2 receptor in: serum concentrations and disease activity, **1033**
disease, stomal adenocarcinoma in *(Case report)*, **1329**
CROKER J. *See* DOWSETT JF, **905**
CRUMP BJ. *See* SITUNAYAKE RD, **1311**
Cryptosporidial infection, enteric, protracted, in selective IgA and saccharomyces opsonin deficiencies *(Case report)*, **714**, *(Letter)*, **1423**
CUCCHIARA S, STAIANO A, BOCCIERI A, DE STEFANO M, CAPOZZI C, MANZI G, CAMERLINGO F, PAONE FM: Effects of cisapride on parameters of oesophageal motility and on the prolonged intraoesophageal pH test in infants with gastro-oesophageal reflux disease, **21**
——, ——, GOBIO CASALI L, BOCCIERI A, PAONE FM: Value of the 24 hour intraoesophageal pH monitoring in children, **129**
CUMMINGS JH. *See* CHACKO A, **106**; GIBSON GR, **679**
CUMMINS AG, LABROOY JT, STANLEY DP, ROWLAND R, SHEARMAN DJC: Quantitative histological study of enteropathy associated with HIV infection, **317**, *(Letter)*, **960**
CUNDY TF, O'GRADY JG, WILLIAMS R: Recovery of menstruation and pregnancy after liver transplantation, **337**
CUOMO R. *See* PIGNATA C, **879**
CUSCHIERI A: Postvagotomy diarrhoea: is there a place for surgical management? *(Leading article)*, **245**
CUVELIER C, MIELANTS H, DE VOS M, VEYS E, ROELS H: Major histocompatibility complex class II antigen (HLA-DR) expression by ileal epithelial cells in patients with seronegative spondylarthropy, **545**
Cyclic adenosine monophosphate production in enterocytes isolated from human duodenal biopsy specimens, effect of vasoactive intestinal peptide on, **1350**
Cyclophosphamide, effect on an animal model of granulomatous bowel disease, **674**
Cyclosporin, interleukin-2, and Crohn's disease, **795**
Cyclosporin A, effect on an animal model of granulomatous bowel disease, **674**
CYNOBER L. *See* ZIEGLER F, **1277**
Cyproterone acetate causing severe hepatitis, *(Case report)*, **556**
Cystic fibrosis, enhanced intestinal glucose and alanine transport in, **817**
fibrosis, pathology of common bile duct stenosis in *(Case report)*, **236**
fibrosis patients with longstanding cholestatis, effect of ursodeoxycholic acid treatment on nutrition and liver function in, **918**
Cytology, fine needle aspiration, of rectal masses, **334**
Cytoprotection against neutrophil derived hypochlorous acid: therapeutic action of 5-aminosalicylic acid in ulcerative colitis, **184**
Cytotoxicity, cell mediated, inhibited by sulphasalazine, **1030**
in vitro, of blood leucocytes from aphthous ulcer patients for oral epithelial cells, effector cells responsible for, **294**

D'ANNA LM. *See* DOWSETT JF, **905**
DADUFALZA VD. *See* KRUGLIAK P, **417**
DAHL K. *See* MADSEN JL, **1003**
DALLEGRI F, OTTONELLO L, BALLESTRERO A, BOGLIOLO F, FERRANDO F, PATRONE F: Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis, **184**
DALY MJ. *See* BARDHAN KD, **745**
DANESHMEND TK, STEIN AG, BHASKAR NK, HAWKEY CJ: Abolition by omeprazole of aspirin induced gastric mucosal injury in man, **514**
DANIELSSON A. *See* SAHLIN S, **100**
DARZI A, REID I, KAY E, MONSON JRT, TANNER WA, KEANE FBV: Piezolelectric lithotripsy and soft tissue injury. Safety limits in the experimental and clinical setting, **1110**
DAS KM. *See* TAKAHASI F, **1016**
DAVARIS P. *See* ARCHIMANDRITIS AJ, **481**
DAVIES JA. *See* SITUNAYAKE RD, **1311**
DAVIS M. *See* BATE CM, **968**; HOLMAN RAE, **504**
——: *See* SITUNAYAKE RD, **1311**
DAWSON A: Sir FA Jones at 80, **492**
DAWSON AA. *See* FEATHERSTONE T, **834**
DAX J. *See* STALLMACH A, **70**
DAY SJ. *See* KENDALL GPN, **1062**
DEBNAM ES. *See* CHESTA J, **660**
DE BUYSER K. *See* HIELE M, **175**
DE DOMBAL FT, PRICE AB, THOMPSON H, WILLIAMS GT, MORGAN AG, SOFTLEY A, CLAMP SE, UNWIN BJ: The British Society of Gastroenterology early gastric cancer/dysplasia survey: an interim report, **115**
DEES A, BATENBURG PL, UMAR HM, MENON RS, VERWEIJ J: *Strongyloides stercoralis* associated with a bleeding gastric ulcer *(Case report)*, **1414**
DE FRANCHIS R. *See* VECCHI M, **482**
DEHN TCB, SHEPHERD HA, COLIN-JONES D, KETTLEWELL MGW, CARROLL NJH: Double blind comparison of omeprazole (40mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring, **509**
DELAMARRE J. *See* FIEVET P, **361**
DELCHIER J: Omeprazole in H, blocker non-responders- author's reply *(Letter)*, **584**
DELVES HT. *See* PLAYFORD RJ, **359**
DE MULDER PHM. *See* VAN KLAVEREN RJ, **953**
DENIZOT Y, SOBHANI I, RAMBAUD J-C, LEWIN M, THOMAS Y, BENVENISTE J: Paf-acether synthesis by *Helicobacter pylori*, **1242**
DeNol *See* Bismuth subcitrate; Tripotassium dicitrato bismuthate
DENT J. *See* WYMAN JB, **639**
DENT NA. *See* GEAR MWL, **1150**
Deoxycholate and an enteric anaerobic bacterial culture supernatant, effects on intestinal calcium absorption and disaccharidase activity, **770**
Derby, city of, Crohn's disease in, **1262**
DE ROOY FWM. *See* HOOGERBRUGGE-VD LINDEN N, **348**
DESAI A. *See* MOSLEY JG, **956**
DESMORAT H. *See* CALES P, **1298**
DE STEFANO M. *See* CUCCHIARA S, **21**
DE VOS M. *See* CUVELIER C, **545**
DEV WIG J. *See* KOCHHAR R, **334**
DEWBURY KC. *See* AYRES RCS, **722**
DHANDE DS. *See* BARDHAN KD, **745**
Diabetic rat, delayed stomach to caecum transit time in, **660**
subjects, non-insulin dependent, plasma insulin, serum lipids and lipoproteins in gall stone disease in: case control study, **344**, *(Letter)* **000**
Diacylglycerol values, low, in colonic adenomas and colorectal cancer, **1041**
DIAMOND T, STIEL D, LUNZER M, WILKINSON M, ROCHE J, POSEN S: Osteoporosis and skeletal fractures in chronic liver disease, **82**
Diarrhoea, acute, in expatriates in Bangladesh *(Letter)*, **123**
enterotoxins from *Clostridium difficile*, **781**
of famine and malnutrition, rat model, **43**, **162**
protracted, familial, lethal, defective jejunal brush border membrane sodium/proton exchange in association with *(Case report)*, **1156**
seemingly pathogen-negative, in HIV type 1, **886**
postvagotomy: is there a place for surgical management *(Leading article)*, **245**
Diet, elemental, in the management of Crohn's disease, ten years' experience with, **1133**
elemental, in treatment of Crohn's disease by gastroenterologists *(Letter)*, **1424**
Dietary fat in modulation of fluid absorption and the secretory responses of rat jejunum to cholera toxin, **1256**
Dietary fibre and refined sugar intake in duodenal ulcer, **993**
fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis, **539**
linoleic acid: low intake and duodenal ulcer, **997**
DILAWARI JB. *See* CHAWLA YK, **213**
DILL S, PAYNE-JAMES JJ, MISIEWICZ JJ, GRIMBLE GK, MCSWIGGAN D, PATHAK K, WOOD AJ, SCRIMGEOUR CM, RENNIE MJ: Evaluation of ^{13}C-urea breath test in the detection of *Helicobacter pylori* and in monitoring the effect of tripotassium dicitrato- bismuthate in non-ulcer dyspepsia, **1237**
DILLINGER HW. *See* HELLSTERN A, **922**
DILLON MJ. *See* JENKINS HR, **194**
Dinner, time of, influence on nocturnal gastric pH *(Letter)*, **364**
Disaccharidase activity and intestinal calcium absorption, effects of an enteric anaerobic bacterial culture supernatant and deoxycholate on, **770**
DI STASI M. *See* SBOLLI G, **1303**

DITSCHUNEIT H. *See* JANOWITZ P, **1407**
DIVE C. *See* COLOMBEL JF, **1345**
Diverticula, Meckel's, *H pylori* infection in *(Letter)*, **243**
DIXON MF. *See* HESSEY SJ, **134**; LANSDOWN M, **977**
DNA analysis, microspectrophotometric, in ulcerative colitis and its application in diagnosis of carcinoma and dysplasia, **1266**
DOBRILLA G: Ranitidine nocte v ranitidine mane and nocte *(Letter)*, **242**
——, IMBIMBO BP, PIAZZI L, BENSI G: Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial, **355**
DODDS WJ. *See* HELM JF, **266**; WYMAN JB, **639**
Dodecapeptide, synthetic, derived from human adenovirus 12, cellular hypersensitivity to, in coeliac disease, **668**
DODGE JA. *See* SAGHER FA, **1256**
DOMSCHKE W. *See* BLUM AL, **825**
DOOLEY JS. *See* BLAKE JC, **556**
DORAN J. *See* FELLOWS IW, **728**
DORIA M. *See* KESHAVARZIAN A, **786**
DORRINGTON L. *See* STEADMAN C, **845**
DOS SANTOS AA. *See* XAVIER-NETO J, **1006**
DOWLING BL. *See* STUDLEY JGN, **867**
DOWNTON J. *See* WYMAN JB, **639**
DOWSETT JF, POLYDOROU AA, VAIRA D, D'ANNA LM, ASHRAF M, CROKER J, SALMON PR, RUSSELL RCG, HATFIELD AR: Needle knife papillotomy, **905**
DOWSETT JF. *See also* JENNINGS PE, **558**
DREXHAGE HA. *See* SELDENRIJK CA, **529**
DRUMMOND G. *See* BERGLUND L, **899**
DUBE R, ROOK GAW, STEELE J, BREALEY R, DWEK R, RADEMACHER T, LENNARD-JONES J: Agalactosyl IgG in inflammatory bowel disease: correlation with C-reactive protein, **431**
DUEHOLM S. *See* GJORUP I, **1411**
DUNWOODIE WMB. *See* JONES RH, **401**
Duodenal bicarbonate secretion in vivo in the rat, effect of bismuth subcitrate and sucralfate on, **26**, *(Letter)* **958**
bile, endoscopically obtained, and gall bladder bile compared, **1407**
biopsy specimens, enterocytes isolated from, effect of vasoactive peptide on cyclic adenosine monophosphate production, **1350**
folds, loss of, allows diagnosis of unsuspected coeliac disease *(Case report)*, **1080**
mucosal biopsy specimens, endoscopic, from dyspeptic patients, inflammatory cell densities in, computer linked image analysis, **858**
ulcer, age of onset of symptoms in, **854**
ulcer and *H pylori* *(Letter)*, **242**
ulcer and low dietary linoleic acid intake, **997**
ulcer and refined carbohydrate intake: case-control study, **993**
ulcer disease, hypergastrinaemic, gastric enterochromaffin-like cells in, **144**
ulcer healing during cimetidine treatment, predictors of, **758**
ulcer healing, inhibition of nocturnal acidity is important but not essential for, **397**
ulcer, omeprazole *v* ranitidine in: multicentre trial, **653**
ulcer patients, effect of food on H_2-receptor blockade in normal subjects and, **148**
ulcer patients, Helicobacter associated gastritis in: the influence of various drugs *(Letter)*, **481**
ulcer recurrence, acyclovir in prevention of, **151**
ulcer resistance to H_2 antagonists and to vagotomy, is antral gastrin important in? **763**
ulcer subjects, sufotidine 600 mg bd virtually eliminates 24 hour intragastric acidity in, **291**
ulcers treated with colloidal bismuth subcitrate, adjuvant antibiotic therapy in, **999**
DWEK R. *See* DUBE R, **431**
DWIVEDI M. *See* MISRA SP, **1144**
Dyspepsia in England and Scotland, **401**
non-ulcer, and peptic ulcer, *H pylori* and gastritis in: ethnic differences in Singapore, **850**
non-ulcer: ^{13}C-urea breath test in the detection of *H pylori* and in monitoring the effect of tripotassium dicitrato-bismuthate, **1237**
non-ulcer, symptoms and gastric histology in, effect of colloidal bismuth subcitrate *(Clinical trial)*, **476**
Dyspeptic patients, longterm oral cisapride improves inter-digestive antroduodenal motility in, **286**
patients, mucosal inflammatory cell densities in endoscopic duodenal biopsy specimens from, **858**
Dysphagia, malignant, trial of laser therapy only and laser therapy followed by endoscopic intubation for palliation of, **252**, *(Letter)*, **1161**
Dysplasia and carcinoma in ulcerative colitis, diagnosis of, microspectrophotometric DNA analysis, **1266**
and early gastric cancer: British Society of Gastroenterology survey, **115**

ECG record during changes in oesophageal pH, **127**
EDMOND M. *See* KATSCHINSKI BD, **993**
Eicosanoid profile of healing colon anastomosis and peritoneal macrophages in the rat, **807**
EINARSSON K. *See* BERGLUND L, **899**; SAHLIN S, **100**
ELDER GH. *See* SEYMOUR DG, **719**
Electromagnetically generated extracorporeal shock waves for fragmentation of extra-and intrahepatic bile duct stones, **222**
ELIAS E. *See* NEUBERGER JM, **1069**
ELLIOTT EJ. *See* WATSON AJM, **170**
ELLIS A. *See* MARSH MN, **32**
ELMES ME: Acrodermatitis enteropathica with normal zinc concentrations *(Letter)*, **243**
EMTESTAM L. *See* BERGLUND L, **899**
Encephalopathy, hepatic, chronic, lactulose resistant, vancomycin hydrochloride in, **702**, *(Letter)*, **1424**
induced by bismuth caused by tripotassium dicitrato bismuthate in a patient with chronic renal failure *(Case report)*, **359**
portosystemic: effects of lactulose and lactitol on protein digestion and metabolism in animal models, **1403**
Endocrine cells containing histamine in the human stomach, **383** *See also* Enteroendocrine cells
Endoprostheses, biliary, clogging of, **913**
Endoscopes, fibreoptic, elimination of high titre HIV from, **657**, *(Letter)*, **1421**
Endoscopic demands in the 90s *(Leading article)*, **125**
intubation following laser therapy for palliation of malignant dysphagia, **252**, *(Letter)*, **1161**
intubation alone in inoperable squamous cell oesophageal cancer, what does radiotherapy add to survival? **750**
Nd:YAG laser treatment of rectosigmoid cancer, **812**
retrograde cholangiopancreatography, future needs for, **1150**
retrograde cholangiopancreatography in pancreatic duct abnormalities in gall stone disease, **1073**
sphincterotomy in sphincter of Oddi dysfunction, clinical and scintigraphic assessment of, **231**
Endoscopy and computed tomography in the management of alimentary tract lipomas *(Case report)*, **550**
of upper gastrointestinal tract, arterial oxygen saturation during, effects of a midazolam/pethidine combination, **270**
Endotoxin induced tumour necrosis factor production by monocytes inhibited by lactulose in vitro, **198**
Enema of small bowel, in non-responsive coeliac disease, **883**
England and Scotland, dyspepsia in, **401**
Entamoeba histolytica, Gal/GalNAc adherence lectin of, binding of proteolytically-degraded human colonic mucin glycoproteins to, **890**
Enteral nitrogen support in surgical patients, **1277**
Enterochromaffin-like cells, gastric, in hypergastrinaemic duodenal ulcer disease, **144**
like cells in rat stomach, serum gastrin concentration effects self replication rate of, **274**
Enteroendocrine cells, kinetics of, implications for their origin, a study of the cholecystokinin and gastrin subpopulations in the mouse, **406**
Enteropathy associated with HIV infection, quantitative histological study of, **317**, *(Letter)*, **960**
Environmental antigen challenge, evolutionary changes in small intestinal mucosa in response to *(Progress report)*, **111**
Eosinophilic gastroenteritis, clinicopathological study, **54**
Eosinophils, activated, in coeliac disease *(Letter)*, **583**
Epithelial dysplasia in Crohn's disease *(Letter)*, **584**
head and neck tumours, mucosal immunodeficiency in smokers and in patients with, **378**
HLA class II expression and T cell number in normal and inflamed human gastric mucosa, **647**
Epithelium, gut, gamma/delta T cells in *(Leading article)*, **841**
Epithelium (ial) *See also* Gall bladder; Ileal; Oral
EPSTEIN O. *See* CHESTA J, **660**, SPITERI MA, **208**
Epstein-Barr virus associated oesophageal ulcers in AIDS, **1223**
ERIKSEN J. *See* RUNE SJ, **151**
ETANCHAUD F. *See* FLOURIE B, **684**
Ethanol in pancreatic juice after oral and intravenous administration, **1411**
luminal, response of rat gastric mucosa to, effect of colloidal bismuth subcitrate, **389**
ETHERINGTON R. *See* CLEMENTS D, **1333**
EVANS DF. *See* PYE G, **1355**
EVANS DG. *See* SMITH JTL, **522**
EVANS DJ. *See* SMITH JTL, **522**
EWEN SWB. *See* FEATHERSTONE T, **834**
Extracorporeal shock wave lithotripsy, piezoelectric, and soft tissue injury, **1410**
shockwaves, electromagnetically generated, for fragmentation of extra- and intrahepatic bile duct stones, **222**
Extrahepatic portal venous obstruction, sclerotherapy in, **213**

Faecal and caecal homogenates, hydrogen and methane production compared in, **684**
incontinence and anorectal physiologic function, efficacy of biofeedback training in improving, **1395**
incontinence, neurogenic, use of the pudendo-anal reflex in, **1051**
FAIRBURN CG, PEVELER RC: Bulimia nervosa and a stepped care approach to management *(Leading article)*, **1220**
FAIRCLOUGH PD. *See* WATSON AJM, **170**

Famine and malnutrition, diarrhoea of, rat model, **43**, **162**
FAN ST: Prediction of severity of acute pancreatitis *(Letter)*, **1419**
FANTI L. *See* TESTONI PA, **286**
FARTHING MJG: British Digestive Foundation *(Letter)*, **731**
——: *See also* MADDEN MV, **247**; WATSON AJM, **170**
Fat incorporated into a liquid test meal, effect on the relation between intragastric distribution and gastric emptying in human volunteers, **1226**
ingestion of, effect on ileostomy effluent, **435**
necrosis, high serum lipase and trypsin activity, and polyarthritis complicating pancreatic carcinoma, *(Case report)*, **953**
See also Dietary fat
Fatty acids, short chain, dilate isolated human colonic resistance arteries, **1391**
FEATHERSTONE T, BAYLISS AP, EWEN SWB, BRUNT PW, DAWSON AA: Obscure anaemia and hepatic dysfunction in Castleman's disease, **834**
FEIGHERY C, WEIR D, WHELAN A: Activated eosinophils in coeliac disease-authors' reply *(Letter)*, **584**
FEIGHERY C. *See also* CAFFREY C, **663**
FELLOWS IW, FREEMAN JG, HOLMES GKT: Crohn's disease in the city of Derby, 1951-85, **1262**
FELLOWS IW, LEACH IH, SMITH PG, TOGHILL PJ, DORAN J: Carcinoid tumour of the common bile duct – a novel complication of von Hippel-Lindau syndrome, **728**
FENTON TR. *See* JENKINS HR, **194**
FERGUSON A. *See* BARTON JR, **378**; O'MAHONY S, **1341**
FERRANDO F. *See* DALLEGRI F, **184**
FERRANDO J. *See* MIKE N, **883**
FEURLE G. *See* BLUM AL, **825**
FEYER E. *See* VIZI ES, **1046**
FEYERABEND C. *See* SRIVASTAVA ED, **1021**
Fibre *See* Dietary fibre
FIELDING JF. *See* LYONS DJ, **838**
FIEVET P, SEVESTRE H, BOUDJELAL M, NOEL LH, KEMENY F, FRANCO D, DELAMARRE J, CAPRON JP: Systemic AA amyloidosis induced by liver cell adenoma *(Case report)*, **361**
FILIPE MI. *See* SILVA S, **1097**
Fine needle aspiration biopsy, guided by ultrasound, in diagnosis of hepatocellular carcinoma, **1303**
needle aspiration cytology of rectal masses, **334**
needle biopsies, histological and cytological, guided by ultrasound, of the pancreas, **930**
Fish oil diet reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis, **539**
Fistula, pancreatico-pleural, and portal vein thrombosis, caused by pancreatic pseudocyst *(Case report)*, **561**
FLORENT C. *See* FLOURIE B, **684**
FLOTH A. *See* STARITZ M, **222**
FLOURIE B, ETANCHAUD F, FLORENT C, PELLIER P, BOUHNIK Y, KAMBAUD J-C: Comparative study of hydrogen and methane production in the human colon using caecal and faecal homogenates, **684**
Fluid absorption and the secretory response of rat jejunum to cholera toxin, modulation by dietary fat, **1256**
Fluid therapy *See* Rehydration solutions
Food, effect on H_2-receptor blockade in normal subjects and in duodenal ulcer, **148**
intake and satiety in man, effect of prefeeding lipid on, **158**
FORBES A, MURRAY-LYON I: Vancomycin in resistant hepatic encephalopathy *(Letter)*, **1424**
——: *See also* CONNOLLY GM, **886**
FORGACS IC. *See* BATE CM, **968**
FORMAN A. *See* TOTTRUP A, **17**
FORNARI F. *See* SBOLLI G, **1303**
FOSTER DN. *See* BATE CM, **968**
FOX R. *See* BILTON D, **236**
Fractures *See* Skeletal fractures
FRANCIS ND. *See* KITCHEN VS, **1223**
FRANCO D. *See* FIEVET P, **361**
Free radicals *See* Oxygen free radicals; Lipid peroxidation
FREEMAN JG. *See* FELLOWS IW, **1262**
FREEMAN TC, PLAYFORD RJ, QUINN C, BEARDSHALL K, POULTER L, YOUNG J, CALAM J: Pancreatic secretory trypsin inhibitor in gastrointestinal mucosa and gastric juice, **1318**
FRENK H. *See* HELLSTERN A, **922**
FREWIN DB. *See* ROBERTS-THOMSON IC, **217**
FRY L. *See* CAFFREY C, **663**
FRYER A. *See* SEYMOUR DG, **719**
FULLARTON GM, BOYD EJS, CREAN GP, HILDITCH TE, MCCOLL KEL: Effect of simulated intragastric haemorrhage on gastric acid secretion, gastric motility, and serum gastrin, **518**
——, HILDITCH T, CAMPBELL A, MURRAY WR: Clinical and scintigraphic assessment of the role of endoscopic sphincterotomy in the treatment of sphincter of Oddi dysfunction, **231**
FUNCH-JENSEN P. *See* TOTTRUP A, **17**
FUSSEK M. *See* LEONHARDT U, **934**
GAIANI S. *See* BOLONDI L, **1306**
Gall bladder bile and endoscopically obtained duodenal bile, comparison of, **1407**
bladder bile and mucosa, interactions between; relevance to gall stone formation *(Progress report)*, **568**
bladder epithelium in gall stone free subjects and patients with gall stones, ultrastructural studies of, **100**, *(Letter)*, **1423**
bladder mucosa and bile, interactions between; relevance to gall stone formation *(Case report)*, **568**
stone disease in non-insulin dependent diabetics, plasma insulin, serum lipids and lipoproteins in, case control study, **344**, *(Letter)*, **000**
stone disease, pancreatic duct abnormalities in, **1073**
stone dissolution with methyl tert-butyl ether: avoiding complications, **922**
stone formation: interactions between gall bladder bile and mucosa *(Progress report)*, **568**
stone patients, hepatic biliary lipid secretion and gall bladder biliary lipid mass in, effect of ursodeoxycholic acid, **226**
stone patients, quantitative ultrastructural studies of gall bladder epithelium in, **100**, *(Letter)*, **1423**
GALLAGHER ND. *See* MCDONALD JA, **725**
GALLAGHER R. *See* CAFFREY C, **663**
GALLOWAY GJ. *See* OBERHAENSLI R, **463**
GALMICHE JP. *See* CLOAREC D, **300**
GANDEVIA SC. *See* WEGMAN EA, **1289**
GARGOT D. *See* CADRANEL JF, **483**
GARNER A. *See* SHORROCK CJ, **26**, **958**; SMITH JTL, **871**
GARTELL P. *See* HOLMAN RAE, **504**
GASBARRINI G. *See* CORAZZA GR, **1080**
GASPAR M. *See* SCHOENBERG MH, **1138**
Gastric acid secretion and changes in urinary acid excretion, relation between, **862**
acid secretion, gastric motility, and serum gastrin, effect of simulated intragastric haemorrhage on, **518**
acidity, gastrin cell number, serum, antral mucosa and luminal gastrin concentration in antral atrophic gastritis, **279**
acidity, nocturnal: inhibition is important but not essential for duodenal ulcer healing, **397**, *(Letter)*, **1088**
adaptive relaxation, abnormal, in patients with gastro-oesophageal reflux, **500**; *(Correction)*, **799**
and oesophageal motor activity in bulimia nervosa, **259**
bicarbonate secretion, human, in vivo, effect of bismuth subcitrate and sucralfate on, **26**; *(Letter)*, **958**
cancer, early, and dysplasia: interim report of British Society of Gastroenterology survey *(Special report)*, **115**
cancer, gastric emptying in, **767**
cancer, marker for: high grade dysplasia of the gastric mucosa, **977**
dysplasia, development in pernicious anaemia, follow up study, **1105**
emptying in fundal gastritis and gastric cancer, **767**
emptying in relation to intragastric distribution of a liquid test meal incorporated with fat, in human volunteers, **1226**
enterochromaffin-like cells in hypergastrinaemic duodenal ulcer disease, **144**
enterochromaffin-like cells of rat, serum gastrin concentration affects the self replication rate of, **274**
histology and symptoms in non-ulcer dyspepsia, effect of colloidal bismuth subcitrate on *(Clinical trial)*, **476**
juice and gastrointestinal mucosa, pancreatic secretory trypsin inhibitor in, **1318**
motility, gastric acid secretion, and serum gastrin, effect of simulated intragastric haemorrhage on, **518**
mucosa, high grade dysplasia of: a marker for gastric cancer, **977**
mucosa, human, in chronic gastritis of the antrum, relation of *H pylori* to, **1230**
mucosa, human, normal and inflamed, T cell number and epithelial HLA class II expression in, **647**
mucosa, of rat, response to presence of luminal ethanol, effect of repeated colloidal bismuth subcitrate, **389**
mucosal cells of pig, isolated: glycoprotein and protein synthesis stimulated by prostaglandins, **414**
mucosal injury induced by aspirin, abolished by omeprazole, **514**
pH, nocturnal, influence of time of dinner on *(Letter)*, **364**
remnant, from Billroth II resection, myoelectrical activity of, **984**
stump carcinoma: risks and pathogenesis *(Leading article)*, **1217**
tissue, cathepsins D and E in, **1250**
ulcer, age of onset of symptoms in, **854**
ulcer and chronic atrophic gastritis, variants of intestinal metaplasia in evolution of, follow up study, **1097**
ulcer, bleeding, *Strongyloides stercoralis* associated with *(Case report)*, **1414**
ulcer, omeprazole v ranitidine in, multicentre trial, **653**
ulcer recurrence reduced after suppression by *H pylori* by cefixime, **973**
ulcer, sucralfate in treatment and prevention of *(Clinical trial)*, **825**
ulcer, symptomatic, comparison of omeprazole and cimetidine in *(Letter)*, **483**
See also Intragastric
Gastrin, antral, and duodenal ulcer resistance to H_2 receptor antagonists and to vagotomy, **763**

cell number, serum, antral mucosa and luminal gastrin concentration and gastric acidity in antral atrophic gastritis, 279
concentration, serum, affects the self replication rate of enterochromaffin like cells in rat stomach, 274
concentration, serum, gastric acid secretion, and gastric motility, effect of simulated intragastric haemorrhage on, 518
effect on liver regeneration after partial hepatectomy in rats, 92
inhibitory factor, absence of, in the IgG fraction of serum from patients with pernicious anaemia, 871
See also Enteroendocrine cells; Hypergastrinaemia
Gastritis and *H pylori* in peptic ulcer and non-ulcer dyspepsia: ethnic differences in Singapore, 850
antral, chronic, relation of *H pylori* to the human gastric mucosa in, 1230
associated with Helicobacter in duodenal ulcer: the influence of various drugs *(Letter)*, 481
atrophic, antral: gastrin cell number, serum, antral mucosa and luminal gastrin concentration and gastric acidity, 279
atrophic, chronic, and gastric ulcer, variants of intestinal metaplasia in the evolution of, follow up study, 1097
chronic, active: tightly spiral shaped bacteria as another cause? 139
chronic, asssociated with helicobacter, bacterial adhesion and disease activity in, 134
fundal, gastric emptying in, 767
lymphocytic, chronic *(Letter)*, 840
lymphocytic – prospective study of its relationship with varioliform gastritis, 282
Gastroduodenal mucosa in uraemia: endoscopy, histology, and helicobacter-like organisms, 1093
Gastroduodenal resistance to the flow of liquid in the rat increased by acute hypervolaemia, 1006
Gastroenteritis, eosinophilic: clinicopathological study, 54
Gastroenterologists and nutritional support *(Letter)*, 483
Gastrointestinal endoscopy *See* Endoscopes; Endoscopic; Endoscopy
intraluminal pH in normal subjects and those with colorectal adenoma or carcinoma, 1355
marker in a study of ileal function, 1120
mucosa and gastric juice, pancreatic secretory trypsin inhibitor in, 1318
transit of a meal, human migrating myolelectric complex in relation to, 1003
Gastro-oesophageal reflux, abnormal gastric adaptive relaxation in patients with, 500 *(Correction)*, 799
reflux after healing of oesophagitis, daytime reduction of, and its value as an indicator of good response to maintenance, 1025
reflux and asthma *(Leading article)*, 1
reflux in Barrett's oesophagus, evaluation of the magnitude of, 964
reflux disease in infants: effects of cisapride on oesophageal motility and acid reflux, 21
reflux disease, reflux patterns and related oesophageal motor activity in, 633
reflux in children, predictive value of oesophageal pH variables, 370
GAUPMANN G. *See* KISS A, 259
GAUTHIER AP. *See* BOURLIERE M, 949
GAVIN JB. *See* THOMSEN LL, 1230
GAZE MN. *See* BARTON JR, 378
GAZZARD BG: Practical advice for the gastroenterologist dealing with symptomatic HIV disease *(Leading article)*, 733
——: *See* also CONNOLLY GM, 886
GEAR MWL, DENT NA, COLIN-JONES DG, LENNARD-JONES JH, COLLEY JRT: Future needs for ERCP: incidence of conditions leading to bile duct obstruction and requirements for diagnostic and therapeutic biliary procedures, 1150
GEARTY J. *See* SITUNAYAKE RD, 1311
GEMMELL CG. *See* MCKINLAY AW, 940
GERIN P. *See* CALES P, 1298
German employees: occupational distribution of inflammatory bowel disease, 1037
GHILLEBERT G, JANSSENS J, VANTRAPPEN G, NEVENS F, PIESSENS J: Ambulatory 24 hour intraoesophageal pH and pressure recordings v provocation tests in the diagnosis of chest pain of oesophageal origin, 738
GHOOS Y. *See* HIELE M, 175
GIBOUDEAU J. *See* ZIEGLER F, 1277
GIBSON GR, CUMMINGS JH, MACFARLANE GT, ALLISON C, SEGAL I, VORSTER HH, WALKER ARP: Alternative pathways for hydrogen disposal during fermentation in the human colon, 679
GILMORE IT: Orocaecal transit time in health and disease *(Leading article)*, 250
GILMOUR H. *See* PARK K, 322, 840
GILVARRY JM. *See* LYONS DJ, 838
GIONCHETTI P, GUARNIERI C, CAMPIERI M, BELLUZZI A, BRIGNOLA C, IANNONE P, MIGLIOLI M, BARBARA L: Scavenger effect of sulphasalazine, 5-aminosalicylic acid, and olsalazine *(Letter)*, 730
GITTLEN SD, SCHULMAN ES, MADDREY WC: Raised histamine concentrations in chronic cholestatic liver disease, 96
GJORUP I, DUEHOLM S, ANDERSEN B, BURCHARTH F: Ethanol in pancreatic juice after oral and intravenous administration, 1411
GLAUMANN H. *See* BROOME U, 468
GLENTHOJ A, SEHESTED M, TORP-PEDERSEN S: Ultrasonically guided histological and cytological fine needle biopsies of the pancreas. Reliability and reproducibility of diagnoses, 930
Gliadin challenge in coeliac disease: signs of increased leakage over jejunal mucosa, 153
Gliadins in food, review of methods for measuring *(Progress report)*, 712
Glucagonoma, increased amino acid clearance and urea synthesis in, *(Case report)*, 946
Glucocorticoids in ileal Crohn's disease, 325
Glucose and alanine transport, enhanced in cystic fibrosis, 817
-6-phosphate dehydrogenase status, normal, severe haemolysis associated with hepatitis A and, 838
Glutathione S-transferases in alcoholic liver disease, 909
Gluten sensitive enteropathy, IgA class reticulin antibodies of human subtype in *(Letter)*, 585
sensitive enteropathy: lectin binding sites in the jejunal mucosa *(Letter)*, 482
See also Coeliac disease
GLUUD C. *See* RUNE SJ, 151
Glycoprotein and protein synthesis in isolated pig gastric mucosal cells is stimulated by prostaglandins, 412
GOBIO CASALI L. *See* CUCCHIARA S, 129
Goblet cell carcinoid of the appendix, 322
GOEBEL M. *See* STARITZ M, 222
GOLDHILL J. *See* BAXTER P, 817
GOLDIN RD, ROSE DSC: Focal nodular hyperplasia of the liver associated with intracranial vascular malformations, 554
——: *See also* JACYNA MR, 714
GOLDMAN JM, BENNETT JR: Gastro-oesophageal reflux and asthma; a common association, but of what clinical importance? *(Leading article)*, 1
GOLDSTEIN R. *See* LIGUMSKY M, 1416
GOODALL A. *See* JENKINS D, 426
GOODE HF, KELLEHER J, WALKER BE: Relation between zinc status and hepatic functional reserve in patients with liver disease, 694
GOODMAN MJ. *See* RILEY SA, 179, 959
GOR D. *See* HANSON PJV, 657
GORDON JH. *See* KESHAVARZIAN A, 786
GORE ME. *See* JONES A, 938
GORMSEN M. *See* RUNE SJ, 151
GOSSUIN A. *See* HAOT J, 282
GOUGH KR. *See* HOLMAN RAE, 504
GOUILLOUD S. *See* CLOAREC D, 300
GOUMA DJ. *See* GREVE JW, 198
GOYVAERTS H. *See* VANDENPLAS Y, 374
GRACE PA, POSTON GJ, WILLIAMSON RCN: Biliary motility, 571
GRAHAM DY. *See* SMITH JTL, 522
GRANOT E. *See* LIGUMSKY M, 1416
GRANT HW, PALMER KR, RIERMESMA RR, OLIVER MF: Duodenal ulcer is associated with low dietary linoleic acid intake, 997
GRAY JG. *See* SHERLOCK DJ, 1329
GREVE JW, GOUMA DJ, LEEUWEN PAMV, BUURMAN WA: Lactulose inhibits endotoxin induced tumour necrosis factor production by monocytes. An in vitro study, 198
GRIFFIN GE. *See* BATMAN PA, 960
GRIFFIN M. *See* SMITH JA, 1350
GRIFFITHS AM. *See* MACK DR, 243
GRIGG D. *See* LOIZOU LA, 812
GRIMBLE GK. *See* DILL S, 1237
GRIPPON P. *See* CADRANEL JF, 483
GROEN AK. *See* COENE PPLO, 913
GROSSE A. *See* STARITZ M, 222
GRUTZKAU A, HANSKI C, HAHN H, RIECKEN EO: Involvement of M cells in the bacterial invasion of Peyer's patches: a common mechanism shared by *Yersinia enterocolitica* and other enteroinvasive bacteria, 1011
GUAN R. *See* KANG JY, 476, 850
GUARNER F. *See* VILASECA J, 539
GUARNIERI C. *See* GIONCHETTI P, 730
GUDMAND-HOYER E. *See* RUMESSEN JJ, 37
Guide wire distance marks for oesophageal dilatation, 564
GULATI P. *See* MISRA SP, 1073
GULLO L, PEZZILLI R, VENTRUCCI M, BARBARA L: Caerulein induced plasma amino acid decrease: a simple, sensitive, and specific test of pancreatic function, 926
——: *See also* SARLES H, 629
GUMMER P: Sir FA Jones at 80, 490
GUMPEL JM. *See* BJARNASON I, 777
GUNSON BK. *See* NEUBERGER JM, 1069
GUPTA I. *See* MOSLEY JG, 956
GUPTA KL. *See* SAKHUJA V, 831
GUPTA NM. *See* KOCHHAR R, 334
GUPTA RR. *See* KAHRILAS PJ, 4
GUPTA SK. *See* KOCHHAR R, 334
GURR MI. *See* BIRD SP, 1403
GUSLANDI M: Sucralfate, bismuth sucitrate, and gastric HCO_3 in humans *(Letter)*, 958
GUSLANDI M, PASSARETTI S, TITTOBELLO A: Towards a better assessment of reflux oesophagitis *(Letter)*, 481
'Gut', opposition to *(Letter)*, 840

GYDE S: Screening for colorectal cancer in ulcerative colitis: dubious benefits and high costs *(Leading article)*, **1089**

H_2 receptor antagonists, duodenal ulcer resistance to, is antral gastrin important? **763**
receptor blockade in normal subjects and in duodenal ulcer, effect of food on, **148**
receptor blockade: omeprazole in non-responders *(Letter)*, **584**
HABOUBI NY. *See* MAXTON DG, **351**
HACKENBERG K. *See* BLUM AL, **825**
Haematemesis and melaena, centralised approach in the management of, **504**
Haeme oxygenase inhibitor Sn-protoporphyrin in primary biliary cirrhosis and idiopathic haemochromatosis, **899**
Haemochromatosis and porphyria cutanea tarda: family study, **719**
idiopathic, and primary biliary cirrhosis, haeme oxygenase inhibitor Sn-protoporphyrin in, **899**
Haemolysis, severe, associated with hepatitis A and normal glucose-6-phosphate dehydrogenase status, **838**
Haemorrhage *See* Intragastric haemorrhage; Peptic ulcer haemorrhage
HAFFEJEE AA. *See* MANOHAR A, **1130**
HAFKENSCHEID JCM. *See* APARICIO-PAGES MN, **1030**; VAN KLAVEREN RJ, **953**
HAHN H. *See* GRUTZKAU A, **1011**
HAKANSON R. *See* LONROTH H, **383**; TIELEMANS Y, **274**
HALL CN. *See* NORTHFIELD TC, **1217**
HALLAN RI. *See* WALDRON DJ, **1284**
HALLETT MB, WILLIAMS JG, HUGHES LE: Scavenger effect of sulphasalazine, 5-aminosalicylic acid, and olsalazine – author's reply *(Letter)*, **730**
——: *See also* WILLIAMS JG, **187**
HALLGREN R. *See* LAVO B, **153**
HALTER F. *See* MERKI HS, **148**
HAMADA Y. *See* HIBI T, **1371**
HAMBERG O. *See* RUMESSEN JJ, **37**
HAMILTON PW. *See* COLLINS JSA, **858**
HAMMER B. *See* BLUM AL, **825**
HAMPSON SE. *See* SMITH JTL, **871**
HAMPTON FJ, MACFADYEN UM: Reproducibility of oesophageal pH monitoring *(Letter)*, **1420**
HANNAN A, CHESNER I, MERKI HS, MANN S, WALT RP: Use of automatic computerised pump to maintain constant intragastric pH, **1246**
HANSEN CP. *See* HEGNHOJ J, **1076**
HANSKI C. *See* GRUTZKAU A, **1011**; STALLMACH A, **70**
HANSON PJV, GOR D, JEFFRIES DJ, COLLINS JV: Elimination of high titre HIV from fibreoptic endoscopes, **657**, *(Letter)*, **1421**
HAOT J, JOURET A, WILLETTE M, GOSSUIN A, MAINGUET P: Lymphocytic gastritis – prospective study of its relationship with varioliform gastritis, **282**
HAOT J, WEYNAND B, JOURET-MOURIN A: Chronic lymphocytic gastritis *(Letter)*, **840**
HAQ G: One minute urease test *(Letter)*, **840**
HAQUE MM. *See* HARRISON DJ, **909**
HARA A. *See* HIBI T, **1371**
HARDCASTLE J. *See* BAXTER P, **817**
HARDCASTLE JD. *See* CHARNLEY RM, **368**; PYE G, **1355**; THOMAS WM, **1294**
HARDCASTLE PT. *See* BAXTER P, **817**
HARMON JW. *See* TAY HV, **11**
HARRIS JRW. *See* KITCHEN VS, **1223**
HARRIS PA. *See* JOHNSON CD, **862**
HARRISON DJ, MAY L, HAYES PC, HAQUE MM, HAYES JD: Glutathione S-transferases in alcoholic liver disease, **909**
HARTLEY MN, WALKER SJ, MACKIE CR: Abnormal gastric adaptive relaxation in patients with gastrooesophageal reflux, **500** *(Correction)*, **799**
HARVEY RF. *See* BATE CM, **968**
HATFIELD ARW: Palliation of malignant obstructive jaundice – surgery or stent? *(Leading article)*, **1339**
HATFIELD ARW. *See also* DOWSETT JF, **905**
HAWKEY CJ. *See* DANESHMEND TK, **514**
HAYAKAWA K. *See* MAROTTA F, **279**
HAYASHI K. *See* TARAO K, **702**
HAYES JD. *See* HARRISON DJ, **909**
HAYES PC. *See* HARRISON DJ, **909**
Head and neck tumours, epithelial, mucosal immunodeficiency in smokers and in patients with, **378**
HEALD J. *See* MAXTON DG, **351**
HEALY MJ. *See* WALSHE K, **770**
Heat probe thermocoagulation and pure alcohol injection in massive peptic ulcer haemorrhage; trial of, **753**
HEATLEY RV. *See* CRABTREE JE, **1033**
HEDDLE R. *See* WYMAN JB, **639**
HEGNHOJ J, HANSEN CP, RANNEM T, SOBIRK H, BJERGLUND ANDERSEN L, ANDERSEN JR: Pancreatic function in Crohn's disease, **1076**
HEIM H-K, OESTMANN A, SEWING K-FR: Stimulation of glycoprotein and protein synthesis in isolated pig gastric mucosal cells by prostaglandins, **412**
HEINDORFF H. *See* ALMDAL TP, **946**
HELBERT M. *See* KITCHEN VS, **1223**
Helicobacter pylori and duodenal ulcer *(Letter)*, **242**
pylori and gastritis in peptic ulcer and non-ulcer dyspepsia: ethnic differences in Singapore, **850**
pylori associated chronic gastritis, bacterial adhesion and disease activity in, **134**
pylori associated gastritis in duodenal ulcer: the influence of various drugs *(Letter)*, **481**
pylori, bridging the credibility gap *(Review article)*, **940**
pylori detected by ^{13}C-urea breath test, **1237**
pylori eradication in Meckel's diverticula *(Letter)*, **1421**
pylori, inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with, **522**
pylori infection in Meckel's diverticula *(Letter)*, **243**
pylori, Paf-acether synthesis by, **1242**
pylori, relation to the human gastric mucosa in chronic gastritis of the antrum, **1230**
pylori suppression by cefixime, reduction of gastric ulcer recurrence after, **973**
HELLERS G. *See* LEIJONMARCK CE, **329**; PERSSON P-G, **1377**
HELLSTERN A, LEUSCHNER M, FRENK H, DILLINGER HW, CASPARY W, LEUSCHNER U: Gall stone dissolution with methyl tert-butyl ether: how to avoid complications, **922**
HELM JF, MASSEY BT, MARTIN CJ, DODDS WJ, HOGAN WJ, ARNDORFER RC: Oesophageal acidification does not increase lower oesophageal sphincter pressure, **266**
HELVEN R. *See* VANDENPLAS Y, **374**
HENRIKSSON R. *See* SAHLIN S, **100**
Hepatectomy, partial, in rats, effect of gastrin on liver regeneration after, **92**
Hepatic alcohol dehydrogenase activity in alcoholics with and without liver disease, **707**
antioxidants and lipid peroxidation in alcoholic liver disease, **1311**
biliary lipid secretion and gall bladder biliary lipid mass in gall stone patients: effect of ursodeoxycholic acid, **226**
duct, common, villous adenoma of *(Case report)*, **558**
dysfunction and obscure anaemia in Castleman's disease *(Case report)*, **834**
encephalopathy, chronic, lactulose resistant, vancomycin hydrochloride in, **702**, *(Letter)*, **1424**
failure and inferior vena caval obstruction in acute Budd-Chiari syndrome: presentation of hereditary protein C deficiency, **949**
fibropolycystic disease, adult, presenting as obstructive jaundice *(Case report)*, **1082**
See also Liver
Hepatitis, autoimmune chronic active, soluble interleukin 2 receptors in, **690**
chronic, portal hypertension in, **339**
severe, caused by cyproterone acetate *(Case report)*, **556**
Hepatitis A and normal glucose-6-phosphate dehydrogenase status, severe haemolysis associated with *(Case report)*, **838**
Hepatocellular carcinoma diagnosed by ultrasound guided fine needle aspiration biopsy, **1303**
carcinoma, spontaneous regression in, *(Case report)*, **722**
Hepatocellular disease and associated vasodilatation: relation to functional organ failure *(Leading article)*, **365**
HESSEY SJ, SPENCER J, WYATT JI, SOBALA G, RATHBONE BJ, AXON ATR, DIXON MF: Bacterial adhesion and disease activity in Helicobacter associated chronic gastritis, **134**
HESSOV I. *See* MORTENSEN FV, **1391**
HEWITT D. *See* BIRD SP, **1403**
HEYWORTH MF: Immunological response to Cryptosporidium species *(Letter)*, **1423**
HIBI T, OHARA M, TODA K, HARA A, OGATA H, IWAO Y, WATANABE N, WATANABE M, HAMADA Y, KOBAYASHI K, AISO S, TSUCHIYA M: In vitro anticolon antibody production by mucosal or peripheral blood lymphocytes from patients with ulcerative colitis, **1371**
HIELE M, GHOOS Y, RUTGEERTS P, VANTRAPPEN G, DE BUYSER K: $^{13}CO_2$ breath test to measure the hydrolysis of various starch formulations in healthy subjects, **175**
HIGHAM SE, READ NW: Effect of ingestion of fat on ileostomy effluent, **435**
HILDITCH TE. *See* FULLARTON GM, **231**, **518**
HINCHLIFFE RFC. *See* BARDHAN KD, **745**
HINSULL SM, BELLAMY D: Effect of repeated colloidal bismuth subcitrate treatment on the response of the rat gastric mucosa to the presence of luminal ethanol, **389**
Hirschsprung's disease, ganglionic and aganglionic colon in, cholinergic neuroeffector transmission, **1046**
HISHON S. *See* WANI M, **127**
Histamine concentrations raised in chronic cholestatic liver disease, **96**
containing cells in the human stomach, **383**
release from gut mast cells from patients with inflammatory bowel diseases, **791**
HITMAN GA. *See* CAFFREY C, **663**
HIV disease, symptomatic: practical advice for the gastroenterologist *(Leading article)*, **733**
high titre: elimination from fibreoptic endoscopes, **657**, *(Letter)*, **1421**
infection, enteropathy associated with, **317**, *(Letter)*, **960**
Type 1, investigation of seemingly pathogen-negative diarrhoea in, **886**
HLA KK. *See* PLAYFORD RJ, **359**
HLA class II expression by epithelium, and T cell number in normal and inflamed human gastric mucosa, **647**

HLA-DP and coeliac disease: family and population studies, **663**
HLA-DR antigen expression by ileal epithelial cells in seronegative spondylarthropathy, **545**
HO MS. *See* WEE A, **1093**
HOBART J. *See* KISS A, **259**
HOBBS FDR. *See* JONES RH, **401**
HOBBS S. *See* JONES A, **938**
HODGSON HJF. *See* PLAYFORD RJ, **359**
HOGAN WJ. *See* HELM JF, **266**
HOHENFELLNER R. *See* STARITZ M, **222**
HOLLANDER D. *See* KRUGLIAK P, **417**
HOLLIS B. *See* MORRIS A, **139**
HOLMAN RAE, DAVIS M, GOUGH KR, GARTELL P, BRITTON DC, SMITH RB: Value of a centralised approach in the management of haematemesis and melaena: experience in a district general hospital, **504**
HOLMFIELD JHM. *See* PRIMROSE JN, **763**
HOOGERBRUGGE-VD, LINDEN N, DE ROOY FWM, JANSEN H, VAN BLANKENSTEIN M: Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia, **348**
HOPKINSON N. *See* BJARNASON I, **777**
HOUGHTON LA, MANGNALL YF, READ NW: Effect of incorporating fat into a liquid test meal on the relation between intragastric distribution and gastric emptying in human volunteers, **1226**
HOWARD J. *See* CHACKO A, **106**
HOWAT JMT. *See* BILTON D, **236**
HOWDLE PD, LOSOWSKY MS: Review of methods for measuring gliadins in food *(Progress report)*, **712**
HOWE SC. *See* VAN LEEUWEN DJ, **339**
HUESKEN J. *See* TAY HP, **11**
HUGHES LE. *See* HALLETT MB, **730**; WILLIAMS JG, **187**
HUIBREGTSE K. *See* COENE PPLO, **913**
HUITFELDT HS. *See* VALNES K, **647**
HULTCRANTZ R. *See* BERGLUND L, **899**; BROOME U, **468**
HUNTER AH. *See* SHORROCK CJ, **26**
HURST A. *See* STARITZ M, **222**
HUTTEMANN W. *See* BLUM AL, **825**
Hydrocortisone, effect on an animal model of granulomatous bowel disease, **674**
Hydrogen and methane production in the human colon compared using caecal and faecal homogenates, **684**
breath test and methane producing status, **300**
disposal during fermentation in the human colon, alternative pathways for, **679**
end-expiratory concentrations, interval sampling of, to quantify carbohydrate malabsorption by means of lactulose standards, **37**
Hypercholesterolaemia, familial, effect of pravastatin on biliary lipid composition and bile acid synthesis in, **348**
Hypergastrinaemia, inappropriate, in asymptomatic healthy subjects infected with *H pylori*, **522**
Hypergastrinaemic duodenal ulcer disease, gastric enterochromaffin-like cells in, **144**
Hypertension. *See* Portal hypertension
Hypervolaemia, acute, increases gastroduodenal resistance to the flow of liquid in the rat, **1006**
Hypnotherapy in irritable bowel syndrome, changes in rectal sensitivity after, **896**
Hypochlorous acid, neutrophil derived, cytoprotection against: potential mechanism for therapeutic action of 5-amino-salicylic acid in ulcerative colitis, **184**
Hyponatraemia in cirrhotic patients with ascites, intravenous albumin infusion for, **204**

IANNONE P. *See* GIONCHETTI P, **730**
Ig, jejunal, and antigliadin antibody secretion in adult coeliac disease, **1345**
IgA and saccharomyces opsonins, selective deficiencies, protracted enteric cryptosporidial infection in, **714**
class reticulin antibodies of human subtype in gluten sensitive enteropathy *(Letter)*, **585**
IgG, agalactosyl, in inflammatory bowel disease: correlation with C-reactive protein, **431**
fraction of serum from patients with pernicious anaemia, absence of gastrin inhibitory factor in, **871**
IgM, low molecular weight, in primary biliary cirrhosis, **88**
IHSE I. *See* ROLNY P, **821**
IISHI H. *See* TATSUTA M, **767**, **973**
IKEDA T. *See* TARAO K, **702**
Ileal brake in the rat, lipid substances activating, **1126**
Crohn's disease, glucocorticoids in, **325**
function, radioactive gastrointestinal marker in, **1120**
hypersecretion induced by starvation in rat, **162**
epithelial cells, HLA-DR expression by, in seronegative spondylarthropathy, **545**
reservoirs, inflammation in: 'pouchitis' *(Leading article)*, 247
Ileoanal reservoir, cancer in: a new late complication? *(Case report)*, **473**, *(Letter)*, **1161**
Ileostomy effluent, effect of ingestion of fat on, **435**
IMBIMBO BP. *See* DOBRILLA G, **355**
Immune modulating agents, effect on an animal model of granulomatous bowel disease, **674**
Immunity, intestinal. *See* Intestinal humoral immunity
Immunodeficiency, mucosal, in smokers and in patients with epithelial head and neck tumours, **378**
syndromes in children: jejunal bacterial overgrowth and intestinal permeability, **879**
Immunoglobulins. *See* Ig; IgA; IgG; IgM
Immunological features of lung lavage cells from primary biliary cirrhosis patients may reflect those seen in pulmonary sarcoidosis, **208**
India, peptic ulcer in *(Letter)*, **123**
Inferior vena cava, obstruction of, and hepatic failure, in acute Budd-Chiari syndrome: presentation of hereditary protein C deficiency, **949**
Inflammatory bowel disease, active: enhanced production of interleukin 1, **686**
bowel disease, agalactosyl IgG in: correlation with C-reactive protein, **431**
bowel disease, animal model, **1358**
bowel disease and tobacco smoke, case control study, **1377**
bowel disease, chronic: T-cellular immune reactions against *Mycobacterium paratuberculosis, M kansasii, M tuberculosis, M avium*, **529**
bowel disease: inhibition of cell mediated cytotoxicity by sulphasalazine, **1030**
bowel disease, macrophage activity in *(Letters)*, **481**, **1086**
bowel disease, occupational distribution among German employees, **1037**
bowel disease, toxic oxygen metabolite production by circulating phagocytic cells in, **187**
bowel diseases: autoimmune disorders? *(Leading article)*, **961**
bowel diseases, histamine release from gut mast cells from patients with, **791**
bowel diseases. *See also* Colitis; Crohn's disease; Ulcerative colitis
cell densities, mucosal, in endoscopic duodenal biopsy specimens from dyspeptic patients, **858**
Insulin, plasma, serum lipids and lipoproteins, in gall stone disease in non-insulin dependent diabetics: case control study, **344**
Interleukin 1 in inflammatory bowel disease – enhanced production during active disease, **686**
2, plasma concentrations of, and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin, **795**
2 receptor: differential expression on lamina propria T cells and macrophages in the intestinal lesions in Crohn's disease and ulcerative colitis, **1365**
2 receptor, soluble, in Crohn's disease, **1033**
2 receptors, soluble, in autoimmune chronic active hepatitis, **690**
Intestinal adaptation, systemic factors and luminal contents in, **311**, *(Letter)*, **959**
calcium absorption and disaccharidase activity, effects of an enteric anaerobic bacterial culture supernatant and deoxycholate on, **770**
glucose and alanine transport, enhanced in cystic fibrosis, **817**
humoral immunity, gut lavage in study of, **1341**
lymphoid tissue: family studies in coeliac disease, **32**
metaplasia, variants of, in the evolution of chronic atrophic gastritis and gastric ulcer, follow up study, **1097**
permeability and jejunal bacterial overgrowth in children with immunodeficiency syndromes, **879**
permeability of polyethylene glycol 400 is regulated by endogenous and exogenous prostanoids. Influence of non-steroidal anti-inflammatory drugs, **417**
Intestine, rat, morphological effects of *Clostridium difficile* enterotoxins, **781**
small, bypassed, rat, systemic factors are trophic in the absence of luminal contents in, **311**, *(Letter)* **959**
small, enema of, in non-responsive coeliac disease, **883**
small, in alcohol fed rats, protein synthesis of muscle fractions from, **305**
small, mucosa. *See* Mucosa of small intestine
small, rabbit and human, experimental stenosis of, flow-pressure-diameter studies, **875**
Intracranial vascular malformations and associated focal nodular hyperplasia of the liver *(Case report)*, **554**
Intragastric acidity, 24 hour, in duodenal ulcer subjects is virtually eliminated by sufotidine, **291**, *(Letter)*, **1087**
haemorrhage, simulated, effect on gastric acid secretion, gastric motility and serum gastrin, **518**
pH, use of automatic computerised pump to maintain constant, **1246**
Intubation. *See* Endoscopic intubation
Irritable bowel syndrome, anorectal manometry in: differences between diarrhoea and constipation predominant subjects, **458**
bowel syndrome, changes in rectal sensitivity after hypnotherapy in, **896**
bowel syndrome, diagnostic value of the Manning criteria in, **77**
bowel syndrome, longterm treatment with cimetropium bromide *(Clinical trial)*, **355**
bowel syndrome, pressure-volume relations of the rectum in, inter- and intraindividual variation, **1062**
ISHIKAWA H. *See* TATSUTA M, **973**
ISLAM S, MCLEAN AJ: Systemic chemotherapy for *Helicobacter pylori* eradication? *(Letter)*, **1421**
ISLAM S. *See also* MCLEAN AJ, **1086**

ITO T. *See* TARAO K, **702**
IWAO Y. *See* HIBI T, **1371**

JACKSON AA. *See* MORAN BJ, **454**
JACOBS A. *See* SEYMOUR DG, **719**
JACYNA MR: Interactions between gall bladder bile and mucosa; relevance to gall stone formation, **568**
JACYNA MR, PARKIN J, GOLDIN R, BARON JH: Protracted enteric cryptosporidial infection in selective immunoglobulin A and saccharomyces opsonin deficiencies, **714**, *(Letter)*, **1423**
JANIN A. *See* COLOMBEL JF, **583**
JANOWITZ HD: Opposition to 'Gut' *(Letter)*, **840**
JANOWITZ P, SWOBODNIK W, WECHSLER JG, ZOLLER A, KUHN K, DITSCHUNEIT H: Comparison of gall bladder bile and endoscopically obtained duodenal bile, **1407**
JANSEN H. *See* HOOGERBRUGGE-VD LINDEN N, **348**
JANSSENS J. *See* GHILLEBERT G, **738**
JASS JR: Colonic mucus and colitis *(Letter)*, **730**
Jaundice, cholestatic, chronic liver disease, and tumour necrosis factor *(Hypothesis)*, **938**
  obstructive, adult hepatic fibropolycystic disease presenting as *(Case report)*, **1082**
  obstructive, malignant – surgery or stent? *(Leading article)*, **1339**
JAYARAJ AP. *See* TOVEY FI, **123**
JEEKEL J. *See* VAN DER HAM AC, **807**
JEFFRIES DJ. *See* HANSON PJV, **657**
JEFFREY GP, SWANSON NR, YARRED LJ, REED WD: Bile duct antibodies crossreacting with blood group antigens in primary sclerosing cholangitis, **698**
Jejunal and circulating lymphocyte subsets in children with coeliac disease, effect of diet and age on, **422**
  bacterial overgrowth and intestinal permeability in children with immunodeficiency syndromes, **879**
  brush border membrane sodium/proton exchange in association with lethal familial protracted diarrhoea *(Case report)*, **1156**
  hypersecretion induced by starvation in rat, **43**
  Ig and antigliadin antibody secretion in adult coeliac disease, **1345**
  mucosa of patients with gluten sensitive enteropathy, lectin binding sites in *(Letter)*, **482**
  mucosa, signs of increased leakage over, during gliadin challenge in coeliac disease, **153**
Jejunum, rat: modulation of fluid absorption and secretory response to cholera toxin by dietary fat, **1256**
  rat, normal and secreting, acetate absorption in, **170**
JENKINS D, GOODALL A, SCOTT BB: Ulcerative colitis: one disease or two? (Quantitative histological differences between distal and extensive disease), **426**
JENKINS HR, FENTON TR, MCINTOSH N, DILLON MJ, MILLA PJ: Development of colonic sodium transport in early childhood and its regulation by aldosterone, **194**
JENNINGS PE, RODE J, CORAL A, DOWSETT J, LEES WR: Villous adenoma of the common hepatic duct: the role of ultrasound in management, **558**
JENNISCHE E. *See* TORRES J, **781**
JENSSEN TG. *See* BERNERSEN B, **989**
JEWELL DP. *See* MAHIDA YR, **1086**; MANTZARIS GJ, **668**
JOHNSEN R. *See* BERNERSEN B, **989**
JOHNSON CD: Coeliac ganglionectomy *(Letter)*, **1335**
JOHNSON CD: Influence of treatment with pancreatic extracts on pancreatic enzyme secretion *(Letter)*, **243**
JOHNSON CD, HARRIS PA, WASTELL C: Quantitative relation between gastric acid secretion and changes in urinary acid excretion, **862**
JOHNSON M. *See* SPITERI MA, **208**
JOHNSTON D. *See* LANSDOWN M, **977**; PRIMROSE JN, **763**
JONES A, SELBY PJ, VINER C, HOBBS S, GORE ME, MCELWAIN TJ: Tumour necrosis factor, cholestatic jaundice, and chronic liver disease, **938**
JONES RB. *See* BARDHAN KD, **745**
JONES RH, LYDEARD SE, HOBBS FDR, KENKRE JE, WILLIAMS EI, JONES SJ, REPPER JA, CALDOW JL, DUNWOODIE WMB, BOTTOMLEY JM: Dyspepsia in England and Scotland, **401**
JONES SJ. *See* JONES RH, **401**
JONSSON JR. *See* ROBERTS-THOMSON IC, **217**
JORGENSEN PE. *See* RASMUSSEN TN, **92**
JOURET-MOURIN A. *See* HAOT J, **282**, **840**
JUBY LD. *See* CRABTREE JE, **1033**
JULKUNEN R. *See* LAAKSO M, **344**, *(Letter)*, **1422**
JUNG M. *See* BLUM AL, **825**
JUNGINGER TH. *See* STARITZ M, **222**

KACHEL G. *See* BLUM AL, **825**
KAESS H. *See* BLUM AL, **825**
KAGNOFF MF: Understanding the molecular basis of coeliac disease *(Leading article)*, **497**
KAHRILAS PJ, GUPTA RR: Mechanisms of acid reflux associated with cigarette smoking, **4**
KAMATH PS, PHILLIPS SF, O'CONNOR MK, BROWN ML, ZINSMEISTER AR: Colonic capacitance and transit in man: modulation by luminal contents and drugs, **443**
KANG JY: Age of onset of symptoms in duodenal and gastric ulcer, **854**
KANG JY, CHAN-WILDE C, WEE A, CHEW R, TI TK: Role of computed tomography and endoscopy in the management of alimentary tract lipomas, **550**
——, TAY HH, WEE A, GUAN R, MATH MV, YAP I: Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia. A double blind placebo controlled study *(Clinical trial)*, **476**
——, WEE A, MATH MV, GUAN R, TAY HH, YAP I, SUTHERLAND IH: *Helicobacter pylori* and gastritis in patients with peptic ulcer and non-ulcer dyspepsia: ethnic differences in Singapore, **850**
——: *See also* WEE A, **1093**
KANG WM. *See* LIN HJ, **753**
KANTHA SS: Oesophageal carcinoma in Sri Lanka *(Letter)*, **242**
KAPEMBWA MS. *See* BATMAN PA, **960**
KAPPAS A. *See* BERGLUND L, **899**
KARAGIANNIS JA. *See* MANTZARIS GJ, **668**
KARIM QN. *See* BARON JH, **242**
KARMELI F. *See* LIGIMSKY M, **686**
KARPATI S, KOSNAI I, TOROK E: IgA class reticulin antibodies of human subtype in gluten sensitive enteropathy *(Letter)*, **585**
KARUBE H. *See* TARAO K, **702**
KATO Y. *See* SAKU T, **1250**
KATSCHINSKI BD, LOGAN RFA, EDMOND M, LANGMAN MJS: Duodenal ulcer and refined carbohydrate intake: a case-control study assessing dietary fibre and refined sugar intake, **993**
KATZ KD. *See* KRUGLIAK P, **417**
KAUR U. *See* CHAWLA YK, **213**
KAWIMBE BM. *See* BINNIE NR, **1051**
KAY E. *See* DARZI A, **1110**
KAYE G. *See* MCCORMICK PA, **204**
KEANE C. *See* O'RIORDAN T, **999**
KEANE CT. *See* WALSHE K, **770**
KEANE FBV. *See* DARZI A, **1110**
KEELING PWN. *See* BATE CM, **968**
KELLEHER J. *See* GOODE HF, **694**
KELLER K. *See* CHADEE K, **890**
KELLER KM, WIRTH S, BAUMANN W, SULE D, BOOTH IW: Defective jejunal brush border membrane sodium/proton exchange in association with lethal familial protracted diarrhoea *(Case report)*, **1156**
KELLOCK D: Sir FA Jones at 80, **489**
KEMENY F. *See* FIEVET P, **361**
KEMPF M. *See* MERKI HS, **148**
KENDALL GPN, THOMPSON DG, DAY SJ, LENNARD-JONES JE: Inter- and intra-individual variation in pressure-voiume relations of the rectum in normal subjects and patients with the irritable bowel syndrome, **1062**
KENKRE JE. *See* JONES RH, **401**
KENNY GNC. *See* MURRAY AW, **270**
Kerckring's folds. *See* Duodenal folds
KERLIN P. *See* STEADMAN C, **845**
KERR K. *See* PARK K, **322**, **840**
KESHAVARZIAN A, MORGAN G, SEDGHI S, GORDON JH, DORIA M: Role of reactive oxygen metabolites in experimental colitis, **786**
KESIEZIE V. *See* KOCHHAR R, **334**
KETTLEWELL MGW. *See* DEHN TCB, **509**
KHUROO MS, SHER-I-KASHMIR: Peptic ulcer in India *(Letter)*, **123**
KING RFGJ. *See* PRIMROSE JN, **763**
KINGHAM JGC: Focal nodular hyperplasia of the liver *(Letter)*, **1335**
KISS A, BERGMANN H, ABATZI TH-A, SCHNEIDER C, WIESNAGROTZKI S, HOBART J, STEINER-MITTELBACH G, GAUPMANN G, KUGI A, STACHER-JANOTTA G, STEINRINGER H, STACHER G: Oesophageal and gastric motor activity in patients with bulimia nervosa, **259**
KITCHEN VS, HELBERT M, FRANCIS ND, LOGAN RPH, LEWIS FA, BOYLSTON AW, PINCHING AJ, HARRIS JRW: Epstein-Barr virus associated oesophageal ulcers in AIDS, **1223**
KNUTSON L. *See* LAVO B, **153**
KOBAYASHI K. *See* HIBI T, **1371**
KOCHHAR R, RAJWANSHI A, DEV WIG J, GUPTA NM, KESIEZIE V, BHASIN DK, MALIK AK, GUPTA SK, MEHTA SK: Fine needle aspiration cytology of rectal masses, **334**
KONTOR E. *See* VIZI ES, **1046**
KONTUREK SJ: Sucralfate, bismuth subcitrate, and gastric HCO in humans *(Letter)*, **958**
KOPP R. *See* SAUTER G, **1041**
KORELITZ BI, LAUWERS GY, SOMMERS SC: Rectal mucosal dysplasia in Crohn's disease, **1382**
KORT WJ. *See* VAN DER HAM AC, **807**
KOSNAI I. *See* KARPATI S, **585**
KRASNER N. *See* BARR H, **252**, **1161**
KRUGLIAK P, HOLLANDER D, LE K, MA T, DADUFALZA VD, KATZ KD: Regulation of polyethylene glycol 400 intestinal permeability by endogenous and exogenous prostanoids. Influence of non-steroidal anti-inflammatory drugs, **417**
KRUSE A. *See* NOLTE H, **791**
KRUSE-ANDERSEN S, WALLIN L, MADSEN T: Reflux patterns and related oesophageal motor activity in gastro-oesophageal reflux disease, **633**
KUCK-BIERE U, VON ENGELHARDT W: Factors affecting the potassium concentration at the mucosal surface of the proximal and the distal colon of guinea pig, **64**

KUGI A. *See* KISS A, **259**
KUHN K. *See* JANOWITZ P, **1407**
KUHNELT P. *See* MUNDLOS S, **1324**
KUMAR D. *See* WALDRON DJ, **1284**
KUMAR P. *See* CAFFREY C, **663**

LAAKSO M, SUHONEN M, JULKUNEN R, PYORALA K: Plasma insulin, serum lipids and lipoproteins in gall stone disease in non- insulin dependent diabetic subjects: a case-control study, **344**, *(Letter)*, **1422**
LABROOY JT. *See* CUMMINS AG, **317**, **960**
Lactulose and lactitol, effects on protein digestion and metabolism in animal models, **1403**
breath hydrogen response to, in healthy subjects: relationship to methane producing status, **300**
inhibits endotoxin induced tumour necrosis factor production by monocytes in vitro, **198**
standards, interval sampling of end-expiratory hydrogen concentrations to quantify carbohydrate malabsorption by means of, **37**
LADEFOGED K, CHRISTENSEN KC: Short bowel syndrome and somatostatin 201-995 *(Letter)*, **124**
LAGOPOLOUS M. *See* PRIMROSE JN, **763**
LAMBERT JR. *See* MCLEAN AJ, **1086**
LAMERS CBHW. *See* APARICIO-PAGES MN, **1030**
Lamina propria T cells and macrophages, differential expression of CD25 (interleukin-2 receptor) on, in intestinal lesions in Crohn's disease and ulcerative colitis, **1365**
Laminin binding proteins in cell membranes of a human colon adenocarcinoma cell line, identification of, **70**
LANGE S. *See* TORRES J, **781**
LANGMAN M: Sir FA Jones at 80, **492**
LANGMAN MJS. *See* KATSCHINSKI BD, **993**
LANSDOWN M, QUIRKE P, DIXON MF, AXON ATR, JOHNSTON D: High grade dysplasia of the gastric mucosa: a marker for gastric carcinoma, **977**
LANZINI A, NORTHFIELD TC: Hepatic biliary lipid secretion and gall bladder biliary lipid mass in gall stone patients: effect of ursodeoxycholic acid, **226**
LANZON-MILLER S. *See* SMITH JTL, **522**
LARSEN S. *See* RUNE SJ, **151**
Laser therapy only and laser therapy followed by endoscopic intubation for the palliation of malignant dysphagia, 252, *(Letter)*, **1161**
treatment, endoscopic, of rectosigmoid cancer, **812**
LAURITSEN K. *See* STAERK LAURSEN L, **1271**
LAUWERS GY. *See* KORELITZ BI, **1382**
LAVO B, KNUTSON L, LOOF L, ODLIND B, HALLGREN R: Signs of increased leakage over the jejunal mucosa during gliadin challenge of patients with coeliac disease, **153**
LAWLER W. *See* BILTON D, **236**
LAWRIE BW. *See* CLEMENTS D, **1333**
LE K. *See* KRUGLIAK P, **417**
LEACH IH. *See* FELLOWS IW, **728**
Lectin binding sites in the jejunal mucosa of patients with gluten sensitive enteropathy *(Letter)*, **482**
LEDINGHAM S. *See* PYE G, **1355**
LEE CH. *See* LIN HJ, **753**
LEE FY. *See* LIN HJ, **753**
LEE SD. *See* LIN HJ, **753**
LEES WR. *See* JENNINGS PE, **558**
LEEUWEN PAMV. *See* GREVE JW, **198**
LEIJONMARCK CE, PERSSON PG, HELLERS G: Factors affecting colectomy rate in ulcerative colitis: an epidemiological study, **329**
LENNARD-JONES J: Sir FA Jones at 80, **491**
LENNARD-JONES JE, MELVILLE DM, MORSON BC, RITCHIE JK, WILLIAMS CB: Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years, **800**
——: *See also* DUBE R, **431**; GEAR MWL, **1150**; KENDALL GPN, **1062**
LENTZE MJ. *See* COTTING J, **918**
LEONHARDT U, SEIDENSTICKER F, FUSSEK M, STOCKMANN F, CREUTZFELDT W: Camostate (FOY-305) improves the therapeutic effect of peritoneal lavage on taurocholate induced pancreatitis, **934**
LE TREUT YP. *See* BOURLIERE M, **949**
Leucocytes. *See* Blood leucocytes; *See also* Monocytes
LEUSCHNER M. *See* HELLSTERN A, **922**
LEUSCHNER U. *See* HELLSTERN A, **922**
LEVI AJ. *See* BJARNASON I, **777**; TEAHON K, **1133**
LEVIN RJ. *See* YOUNG A, **43**, **162**
LEVY E. *See* ZIEGLER F, **1277**
LEVY G. *See* WAKEFIELD A, **239**
LEWIN M. *See* DENIZOT Y, **1242**
LEWIS FA. *See* KITCHEN VS, **1223**
LI BASSI S. *See* BOLONDI L, **1306**
LIGUMSKY M, GRANOT E, BRANSKI D, STANKIEWICZ H, GOLDSTEIN R: Isolated lipase and colipase deficiency in two brothers *(Case report)*, **1416**
LIGUMSKY M, SIMON PL, KARMELI F, RACHMILEWITZ D: Role of interleukin 1 in inflammatory bowel disease – enhanced production during active disease, **686**
LIN HJ, LEE FY, KANG WM, TSAI YT, LEE SD, LEE CH: Heat probe thermocoagulation and pure alcohol injection in massive peptic ulcer haemorrhage: a prospective, randomised controlled trial, **753**
LINDE J. *See* RUNE SJ, **151**
LINDSTROM E. *See* ROLNY P, **821**
LINEHAN IP. *See* STUDLEY JGN, **867**
Linoleic acid, low intake and duodenal ulcer, **997**
Lipase and colipase deficiency, isolated, in two brothers *(Case report)*, **1416**
and trypsin activity, high, in serum, fat necrosis and polyarthritis complicating pancreatic carcinoma, **953**
Lipid peroxidation and hepatic antioxidants in alcoholic liver disease, **1311**
prefeeding, effect on food intake and satiety in man, **158**
substances activating the ileal brake in the rat, **1126**
See also Biliary lipid
Lipids and lipoproteins, serum, and plasma insulin in gall stone disease in non-insulin dependent diabetics: case control study, **344**
Lipodystrophy, partial, in coeliac disease *(Case report)*, **717**
Lipomas of the alimentary tract, computed tomography and endoscopy in the management of *(Case report)*, **550**
Lithotripsy. *See* Extracorporeal shockwave(s)
Liver cell adenoma inducing systemic AA amyloidosis *(Case report)*, **361**
disease, alcoholic, glutathione S-transferases in, **909**
disease, alcoholic, lipid peroxidation and hepatic anti- oxidants in, **1311**
disease, chronic, cholestatic jaundice and tumour necrosis factor *(Hypothesis)*, **938**
disease, chronic cholestatic, raised histamine concentrations in, **96**
disease, chronic, osteoporosis and skeletal fractures in, **82**
disease, human: study with P-31 magnetic resonance spectroscopy, **463**
disease, zinc status and hepatic functional reserve in, **694**
enzymes, rises in, and morphine induced pain after cholecystectomy: sympathetic activation? **217**
focal nodular hyperplasia associated with intracranial vascular malformations *(Case report)*, **554**, *(Letter)*, **1335**
function and nutrition in cystic fibrosis patients with longstanding cholestasis, effects of ursodeoxycholic acid on, **918**
histology and follow up of 68 patients with ulcerative colitis and normal liver function tests, **468**
nodular regenerative hyperplasia, CREST syndrome and primary biliary cirrhosis *(Letter)*, **1335**
nodular regenerative hyperplasia mimicking cirrhosis *(Case report)*, **725**
regeneration after partial hepatectomy in rats, effect of gastrin on, **92**
squamous carcinoma in, **1333**
transplantation, recovery of menstruation and pregnancy after, **337**
transplantation, referral of patients with primary biliary cirrhosis for, **1069**
LOBO AJ. *See* CRABTREE JE, **1033**
LOBO-YEO A, MIELI-VERGANI G, MOWAT AP, VERGANI D: Soluble interleukin 2 receptors in autoimmune chronic active hepatitis, **690**
LOENING-BAUCKE V: Efficacy of biofeedback training in improving faecal incontinence and anorectal physiologic function, **1395**
LOGAN RFA. *See* KATSCHINSKI BD, **993**; OLIVER SE, **750**
LOGAN RPH. *See* KITCHEN VS, **1223**
LOIZOU LA, GRIGG D, BOULOS PB, BOWN SG: Endoscopic Nd:YAG laser treatment of rectosigmoid cancer, **812**
LONG RG. *See* SMITH JA, **1350**
LONNROTH I. *See* TORRES J, **781**
LONROTH H, HAKANSON R, LUNDELL L, SUNDLER F: Histamine containing endocrine cells in the human stomach, **383**
LOOF L. *See* LAVO B, **153**
LOSOWSKY MS. *See* HOWDLE PD, **712**; THORNTON JR, **1159**
LOVE AHG. *See* COLLINS JSA, **858**
LUCAS S. *See* RILEY SA, **179**
LUNDELL L. *See* LONROTH H, **383**
Lung lavage cells from patients with primary biliary cirrhosis: immunological features may reflect those seen in pulmonary sarcoidosis, **208**
LUNZER M. *See* DIAMOND T, **82**
LYDEARD SE. *See* JONES RH, **401**
Lymph node hyperplasia. *See* Castleman's disease
Lymphocyte subsets, jejunal and circulating, in children with coeliac disease, effect of diet and age on, **422**
Lymphocytes, mucosal, or peripheral blood, from patients with ulcerative colitis, in vitro anticolon antibody production by, **1371**
Lymphocytes. *See also* T cells
Lymphocytic gastritis. *See under* Gastritis
LYONS DJ, GILVARRY JM, FIELDING JF: Severe haemolysis associated with hepatitis A and normal glucose-6-phosphate dehydrogenase status, **838**

M cells, involvement in the bacterial invasion of Peyer's patches, **1011**
MA T. *See* KRUGLIAK P, **417**
MCCAUGHAN GW. *See* MCDONALD JA, **725**
MCCAUGHEY G. *See* SAGHER FA, **1256**
MCCOLL KEL. *See* FULLARTON GM, **518**
MCCORMICK PA, CHRONOS N, BURROUGHS AK, MCINTYRE N, MCLAUGHLIN JE: Pancreatic pseudocyst causing portal vein thrombosis and pancreaticopleural fistula *(Case report)*, **561**
MCCORMICK PA, MISTRY P, KAYE G, BURROUGHS AK, MCINTYRE N: Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites, **204**

MCDONALD JA, PAINTER DM, GALLAGHER ND, MCCAUGHAN GW: Nodular regenerative hyperplasia mimicking cirrhosis of the liver, 725
MACDONALD TT. *See* CHOY MY, 1365; VINEY J, 841
MCELWAIN TJ. *See* JONES A, 938
MACFADYEN UM. *See* HAMPTON FJ, 1420
MACFARLANE GT. *See* GIBSON GR, 679
McGealey, Shirley - Technical Editor, appreciation, 732
MCINTOSH N. *See* JENKINS HR, 194
MCINTYRE A. *See* STEADMAN C, 845
MCINTYRE N. *See* BLAKE JC, 536; MCCORMICK PA, 204, 561
MACK DR, GRIFFITHS AM: Acrodermatitis enteropathica with normal zinc concentrations *(Letter)*, 243
MCKENNA D. *See* O'RIORDAN T, 999
MCKENZIE H, MAIN J, PENNINGTON CR, PARRATT D: Antibody to selected strains of *Saccharomyces cerevisiae* (baker's and brewer's yeast) and *Candida albicans* in Crohn's disease, 536
MACKIE CR. *See* HARTLEY MN, 500
MCKIERNAN J. *See* O'MAHONY D, 717
MCKINLAY AW, UPADHYAY R, GEMMELL CG, RUSSELL RI: *Helicobacter pylori*: bridging the credibility gap *(Review article)*, 940
MACKINTOSH P. *See* CAFFREY C, 663
MCLAUGHLIN JE. *See* MCCORMICK PA, 561
MCLEAN AJ, ISLAM S, LAMBERT JR: Anomalous short plasma half life in a patient intoxicated with bismuth subcitrate *(Letter)*, 1086
MCLEAN AJ. *See also* ISLAM S, 1421
MCLEOD R. *See* STERN H, 473
MCMAHON RFT, BABBS C, WARNES TW: CREST syndrome . . . *(Reply to letter)*, 484
——: *See also* BILTON D, 236
MCMASTER C. *See* SAGHER FA, 1256
MCMASTER P. *See* NEUBERGER JM, 1069
Macrophage activity in inflammatory bowel disease *(Letters)*, 481, 1086
Macrophages and T cells from lamina propria, differential expression of CD25 (interleukin-2 receptor) on, in intestinal lesions in Crohn's disease and ulcerative colitis, 1365
peritoneal, and healing colon anastomosis in the rat, eicosanoid profile of, 807
MCSWIGGAN D. *See* DILL S, 1237
MADDEN MV, FARTHING MJG, NICHOLLS RJ: Inflammation in ileal reservoirs: 'pouchitis' *(Leading article)*, 247
MADDREY WC. *See* GITTLEN SD, 96
MADSEN JL, DAHL K: Human migrating myoelectric complex in relation to gastrointestinal transit of a meal, 1003
MADSEN T. *See* KRUSE-ANDERSEN S, 633
MAEDA K. *See* OKADA M, 758
MAGAZZU G. *See* BARRESI G, 482
Magnetic resonance spectroscopy. *See* Phosphorus-31
MAHIDA YR, JEWELL DP: Macrophage activity in inflammatory bowel disease *(Letter)*, 1086
MAILLOT A. *See* BOURLIERE M, 949
MAIN J. *See* MCKENZIE H, 536
MAINGUET P. *See* HAOT J, 282
Major histocompatibility complex. *See* HLA-DP; HLA-DR
MALAGELADA J-R. *See* VILASECA J, 539
MALIK AK. *See* KOCHHAR R, 334
MALIK N. *See* SAKHUJA V, 831
Malnutrition and famine, diarrhoea of, investigations using a rat model, 43, 162
MANEGOLD BC. *See* BLUM AL, 825
MANGNALL YF. *See* HOUGHTON LA, 1226
MANI V. *See* RILEY SA, 179, 959
MANN S. *See* HANNAN A, 1246
Manning criteria in irritable bowel syndrome, diagnostic value of, 77
MANOHAR A, SIMJEE AE, HAFFEJEE AA, PETTENGELL KE: Symptoms and investigative findings in 145 patients with tuberculous peritonitis diagnosed by peritoneoscopy and biopsy over a five year period, 1130
MANTZARIS GJ, KARIAGIANNIS JA, PRIDDLE JD, JEWELL DP: Cellular hypersensitivity to a synthetic dodecapeptide derived from human adenovirus 12 which resembles a sequence of A-gliadin in patients with coeliac disease, 668
MANZI G. *See* CUCCHIARA S, 21
MARAN AGD. *See* BARTON JR, 378
MAROTTA F, HAYAKAWA K, MIKAMI Y, MORELLO P, SUGAI M, MORITA T: Relationship between gastrin cell number, serum, antral mucosa and luminal gastrin concentration and gastric acidity in antral atrophic gastritis, 279
MARSH MN: Grains of truth: evolutionary changes in small intestinal mucosa in response to environmental antigen challenge *(Progress report)*, 111
MARSH MN, BJARNASON I, SHAW J, ELLIS A, BAKER R, PETERS TJ: Studies of intestinal lymphoid tissue. XIV. HLA status, mucosal morphology, permeability and epithelial lymphocyte populations in first degree relatives of patients with coeliac disease, 32
MARTIN CJ. *See* HELM JF, 266
MARTINEZ M. *See* VILASEACA J, 539
MARTINEZ DE HARO LF. *See* PARRILLA P, 964
MASAKI T. *See* SUZUKI K, 1266
MASCART-LEMONE F. *See* COLOMBEL JF, 1345
MASINI JP. *See* ZIEGLER F, 1277
MASSEY BT. *See* HELM JF, 266
Mast cells, gut, from patients with inflammatory bowel diseases, histamine release from, 791
MATH MV. *See* KANG JY, 476, 850
MATHAI E. *See* O'RIORDAN T, 999
MATHAN VI. *See* ROLSTON DDK, 1115
MATSUMOTO K. *See* MURAOKA M, 526
MATTHEWS CH. *See* PLAYFORD RJ, 359
MAXTON DG: Guide wire distance marks for oesophageal dilatation, 564
MAXTON DG, HEALD J, WHORWELL PJ, HABOUBI NY: Controlled trial of Pyrogastrone and cimetidine in the treatment of reflux oesophagitis *(Clinical trial)*, 351
——: *See also* PRIOR A, 458
MAY L. *See* HARRISON DJ, 909
Meckel's diverticula, *H pylori* infection in *(Letter)*, 243
MEHTA SK. *See* KOCHHAR R, 334
MEIJER CJLM. *See* SELDENRIJK CA, 529
MELA GS, CAPUTO E, VILLA G, SAVARINO V, ZENTILIN P: Intragastric acidity and serum gastrin after sufotidine *(Letter)*, 1087
MELA GS. *See also* SAVARINO V, 364, 584
Melaena and haematemesis, centralised approach in the management of, 504
MELTON LJ. *See* TALLEY NJ, 77
MELVILLE DM. *See* LENNARD-JONES JE, 800
MELZNER I. *See* SCHOENBERG MH, 1138
MENON GG. *See* ARMBRECHT U, 1105
MENON RS. *See* DEES A, 1414
Menstruation, recovery of, and pregnancy after liver transplantation, 337
MERKI HS, HALTER F, WILDER-SMITH C, ALLEMANN P, WITZEL L, KEMPF M, ROEHMEL J, WALT RP: Effect of food on H_2-receptor blockade in normal subjects and duodenal ulcer patients, 148
MERKI HS. *See also* HANNAN A, 1246
Mesalazine, disposition of 5-aminosalicylic acid by, in patients with ulcerative colitis, 1271
Mesenteric arteritis, 956
Methane and hydrogen production in the human colon compared using caecal and faecal homogenates, 684
producing status in relation to breath hydrogen response to lactulose, 300
Methotrexate, effect on an animal model of granulomatous bowel disease, 674
Methyl tert-butyl ether for gall stone dissolution: avoiding complications, 922
MEUWISSEN SGM. *See* SELDENRIJK CA, 529
MEYER ZUM BUSCHENFELDE K and H. *See* STARITZ M, 222
Midazolam/pethidine combination: effects on arterial oxygen saturation during upper gastrointestinal endoscopy, 270
MIELANTS H. *See* CUVELIER C, 545
MIELI-VERGANI G. *See* LOBO-YEO A, 690
MIGLIOLI M. *See* GIONCHETTI P, 730
MIKAMI Y. *See* MAROTTA F, 279
MIKE N, UDESHI U, ASQUITH P, FERRANDO J: Small bowel enema in non-responsive coeliac disease, 883
MILDENBERGER P. *See* STARITZ M, 222
MILLA PJ. *See* JENKINS HR, 194
MILLER ARO. *See* RAMAGE JK, 123
MILLWARD-SADLER GH. *See* AYRES RCS, 722
MINE K. *See* MURAOKA M, 526
MINER PB. *See* SUN WM, 1056
MIREYLEES SE. *See* SMITH JA, 1350
MISIEWICZ G: Sir FA Jones at 80, 492
MISIEWICZ JJ. *See* PAYNE-JAMES JJ, 1161; DILL S, 1237
MISRA SP, DWIVEDI M: Pancreaticobilary ductal union, 1144
MISRA SP, GULATI P, CHOUDHARY V, ANAND BS: Pancreatic duct abnormalities in gall stone disease: an endoscopic retrograde cholangiopancreatographic study, 1073
MISTRY P. *See* MCCORMICK PA, 204
MITCHELL IC, TURK JL: Effect of the immune modulating agents cyclophosphamide, methotrexate, hydrocortisone, and cyclosporin A on an animal model of granulomatous bowel disease, 674
MITRA SK. *See* CHAWLA YK, 213
MIZUNO T. *See* TARAO K, 702
MOHAMED ARE, AL KARAWI MA, YASAWY MI: Schistosomal colonic disease, 439
Molecular basis of coeliac disease *(Leading article)*, 497
MONACO G. *See* PIGNATA C, 879
Monocytes, endotoxin induced tumour necrosis factor production by, inhibited by lactulose in vitro, 198
MONSON JRT. *See* DARZI A, 1110
MOORE R. *See* SAGHER FA, 1256
MORAN BJ, JACKSON AA: 15N-urea metabolism in the functioning human colon: luminal hydrolysis and mucosal permeability, 454
MORANCHO J. *See* VIDAL F, 707
MOREL P, ALEXANDER-WILLIAMS J, ROHNER A: Relation between flow-pressure-diameter studies in experimental stenosis of rabbit and human small bowel, 875
MORELLO P. *See* MAROTTA F, 279
MORGAN AG. *See* DE DOMBAL FT, 115
MORGAN G. *See* KESHAVARZIAN A, 786
MORIOKA Y. *See* SUZUKI K, 1266

MORITA T. *See* MAROTTA F, **279**
Morphine induced pain and rises in liver enzymes after cholecystectomy: sympathetic activation? **217**
MORRAN CG. *See* MURRAY AW, **270**
MORRIS A, RAFIQ ALI M, THOMSEN L, HOLLIS B: Tightly spiral shaped bacteria in the human stomach: another cause of active chronic gastritis?, **139**
MORRIS JA. *See* COUPE M, **144**
MORRIS P. *See* BARDHAN KD, **745**
MORSIANI E. *See* CASELLI M, **1423**
MORSON BC: Sir FA Jones at 80, **490**
——: *See also* LENNARD-JONES JE, **800**
MORTENSEN FV, NIELSEN H, MULVANY MJ, HESSOV I: Short chain fatty acids dilate isolated human colonic resistance arteries, **1391**
MORTON CL. *See* ALBERT V, **311**
MOSLEY JG, DESAI A, GUPTA I: Mesenteric arteritis, **956**
Motility. *See* Antroduodenal; Biliary; Oesophageal
Motor activity. *See* Gastric and oesophageal; Oesophageal
neuropathy and reduced filling of the rectum in chronic intractable constipation, **1284**
MOUNTFORD RA. *See* BATE CM, **968**
MOWAT AP. *See* LOBO-YEO A, **690**
Mucosa of small intestine: evolutionary changes in response to environmental antigen challenge *(Progress report)*, **111**
Mucosal immunodeficiency in smokers and in patients with epithelial head and neck tumours, **378**
or peripheral blood lymphocytes from patients with ulcerative colitis, in vitro anticolon antibody production by, **1371**
surface of the proximal and distal colon of guinea pig: factors affecting potassium concentration, **64**
Mucosa(l). *See also* Duodenal; Gall bladder; Gastric; Gastroduodenal; Jejunal; Rectal
MULLEN B. *See* STERN H, **473**
MULVANY MJ. *See* MORTENSEN FV, **1391**
MULVIHILL C. *See* TALLEY NJ, **77**
MUNDLOS S, KUHNELT P, ADLER G: Monitoring enzyme replacement treatment in exocrine pancreatic insufficiency using the cholesteryl octanoate breath test, **1324**
MURAOKA M, MINE K, MATSUMOTO K, NAKAI Y, NAKAGAWA T: Psychogenic vomiting: the relation between patterns of vomiting and psychiatric diagnosis, **526**
MURRAY AW, MORRAN CG, KENNY GNC, ANDERSON JR: Arterial oxygen saturation during upper gastrointestinal endoscopy: the effects of a midazolam/pethidine combination, **270**
MURRAY WR. *See* FULLARTON GM, **231**
MURRAY-LYON I. *See* FORBES A, **1424**
Muscle fractions from small intestine in alcohol fed rats, protein synthesis of, **305**
MUTO T. *See* SUZUKI K, **1266**
Mycobacterium paratuberculosis, M kansasii, M tuberculosis, M avium, T-cellular immune reactions against, in patients with chronic inflammatory bowel disease, **529**
Myoelectric complex, migrating, human, in relation to gastrointestinal transit of a meal, **1003**
Myoelectrical activity of the Billroth II gastric remnant, **984**
signals, colonic, recorded with intramuscular electrodes in the human rectosigmoid in vivo, concordance between, **1289**

NAIK KS. *See* PRIMROSE JN, **763**
NAKAGAWA T. *See* MURAOKA M, **626**
NAKAI Y. *See* MURAOKA M, **526**
NANI E. *See* PIGNATA C, **879**
Natural killer cell activity and sulphasalazine, **1031**
NDARATHI C. *See* CHADEE K, **890**
NEALE G: B_{12} binding proteins, **59**
Neck tumours. *See* Head and neck tumours
Needle biopsies. *See* Fine needle
knife papillotomy: how safe and how effective? **905**
NEMETH J. *See* COLOMBEL JF, **1345**
NERLICH A. *See* SAUTER G, **1041**
NEUBERGER JM, GUNSON BK, BUCKELS JAC, ELIAS E, MCMASTER P: Referral of patients with primary biliary cirrhosis for liver transplantation, **1069**
NEUMANN CS: Elimination of high titre HIV from fibreoptic endoscopes *(Letter)*, **1421**
Neuropathy. *See* Motor neuropathy
Neutrophil derived hypochlorous acid, cytoprotection against, potential mechanism for therapeutic action of 5-aminosalicylic acid in ulcerative colitis, **184**
NEVENS F. *See* GHILLEBERT G, **738**
NEWBOLD KM, O'CONNOR HJ: *Helicobacter pylori* infection in Meckel's diverticula *(Letter)*, **243**
NEWMAN P. *See* CLEMENTS D, **1333**
NIEBEL W. *See* SINGER MV, **1335**
NIELSEN H. *See* MORTENSEN FV, **1391**
Nitrogen support, enteral, in surgical patients, **1277**
NIVEN MJ. *See* CAFFREY C, **663**
NOEL LH. *See* FIEVET P, **361**
NOLTE H, SPJELDNAES N, KRUSE A, WINDELBORG B: Histamine release from gut mast cells from patients with inflammatory bowel diseases, **791**
NOMOTO T. *See* TARAO K, **702**
Non-steroidal anti-inflammatory drug enteropathy, experimental, in rat: effect of thromboxane synthetase inhibitors, **1358**
anti-inflammatory drug enteropathy, treatment of, **777**
anti-inflammatory drugs, influence on regulation of polyethylene glycol 400 intestinal permeability by endogenous and exogenous prostanoids, **417**
NORTHFIELD TC, HALL CN: Carcinoma of the gastric stump: risks and pathogenesis *(Leading article)*, **1217**
NORTHFIELD TC. *See also* LANZINI A, **226**
Notes **124**, **244**, **364**, **485**, **732**, **840**, **960**, **1088**, **1161**, **1338**
NSAID. *See* Non-steroidal anti-inflammatory drug
Nutcracker, neurosis, or sampling bias? *(Leading article)*, **736**
Nutrition and liver function in cystic fibrosis patients with longstanding cholestasis, effects of ursodeoxycholic acid on, **918**
Nutritional support and gastroenterologists *(Letter)*, **483**
NWOKOLO CU. *See* SMITH JTL, **522**

OBERHAENSLI R, RAJAGOPALAN B, GALLOWAY GJ, TAYLOR DJ, RADDA GK: Study of human liver disease with P-31 magnetic resonance spectroscopy, **463**
Occupational distribution of inflammatory bowel disease among German employees, **1037**
O'CONNOR HJ. *See* NEWBOLD KM, **243**
O'CONNOR MK. *See* KAMATH PS, **443**
ODLIND B. *See* LAVO B, **153**
Oesophageal achalasia. *See* Achalasia
acidification and lower oesophageal sphincter pressure, **266**
and gastric motor activity in bulimia nervosa, **259**
cancer, squamous cell, inoperable, what does radiotherapy add to survival over endoscopic intubation alone? **750**
carcinoma in Sri Lanka *(Letter)*, **242**
dilatation, guide wire distance marks for, **564**
injury, peptic, in rabbits, reduced by bismuth subsalicylate, **11**
motility and acid reflux in infants with gastro-oesophageal reflux disease, effects of cisapride on, **21**
motor activity and reflux patterns in gastro-oesophageal reflux disease, **633**
origin of chest pain *(Leading article)*, **736**
origin of chest pain, establishing, ambulatory 24 hour intraoesophageal pH and pressure recordings v provocation tests, **738**
pH, ECG record during changes in, **127**
pH monitoring, continuous, for 24 hours, in infants and children, reproducibility of, **374**, *(Letter)*, **1420**
pH monitoring in children, for 24 hours, value of, **129**
pH variables in children with gastro-oesophageal reflux, predictive value of, **370**
rupture, intramural, spontaneous, **845**
sphincter, lower, control of belching by, **639**
sphincter, lower, oesophageal acidification does not increase pressure, **266**
ulcers associated with Epstein-Barr virus in AIDS, **1223**
varices, large, in patients with cirrhosis, incidence of, **1298**
Oesophagitis, erosive, refractory to high dose cimetidine, omeprazole in, **745**
gastro-oesophageal reflux after healing, daytime reduction of, and its value as an indicator of good response to maintenance, **1025**
reflux, comparison of omeprazole and cimetidine, **968**
reflux: controlled trial of Pyrogastrone and cimetidine *(Clinical trial)*, **351**
reflux, erosive, symptomatic, omeprazole v cimetidine, double blind comparison of, **509**
reflux, towards a better assessment of *(Letter)*, **481**
Oesophagus, Barrett's, evaluation of the magnitude of gastro-oesophageal reflux in, **964**
OESTMANN A. *See* HEIM H-K, **412**
OGATA H. *See* HIBI T, **1371**
OGILVIE AL. *See* STUDLEY JGN, **867**
O'GRADY JG. *See* CUNDY TF, **337**
OHARA M. *See* HIBI T, **1371**
OKABE H. *See* SAKU T, **1250**
OKADA M, YAO T, MAEDA K, YAMAMOTO T, SAIGENJI K, OKADA Y, SAKAMOTO K, TANAKA K: Predictors of duodenal ulcer healing during treatment with cimetidine, **758**
OKADA T. *See* TARAO K, **702**
OKADA Y. *See* OKADA M, **758**
OKUDA S. *See* TATSUTA M, **767**, **973**
OLAISON G, SJODAHL R, TAGESSON C: Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation, **325**
OLAISON G. *See also* ROLNY P, **821**
OLESEN M. *See* RUNE SJ, **151**
OLIVER MF. *See* GRANT HW, **997**
OLIVER SE, ROBERTSON CS, LOGAN RFA, SOKAL M, PEARSON JCG, ATKINSON M: What does radiotherapy add to survival over endoscopic intubation alone in inoperable squamous cell oesophageal cancer? **750**
OLLIVIER JM. *See* ZIEGLER F, **1277**
Olsalazine, disposition of 5-aminosalicylic acid by, in patients with ulcerative colitis, **1271**

sulphasalazine, and 5-aminosalicylic acid, scavenger effect of *(Letter)*, **730**
OLSEN PS. *See* RASMUSSEN TN, **92**
O'MAHONY D, O'MAHONY S, WHELTON MJ, MCKIERNAN J: Partial lipodystrophy in coeliac disease, **717**
O'MAHONY S, BARTON JR, CRICHTON S, FERGUSON A: Appraisal of gut lavage in the study of intestinal humoral immunity, **1341**
O'MAHONY S. *See also* O'MAHONY D, **717**
Omeprazole: abolition of aspirin induced gastric mucosal injury in man, **514**
and cimetidine in reflux oesophagitis, comparison of, **968**
and cimetidine in symptomatic erosive reflux oesophagitis, double blind comparison of, **509**
and cimetidine in symptomatic gastric ulcer, comparison of *(Letter)*, **483**
and ranitidine in duodenal or gastric ulcer, comparison of: multicentre trial, **653**
in erosive oesophagitis refractory to high dose cimetidine and ranitidine, **745**
in H_2 blocker non-responders *(Letter)*, **584**
O'MOORE RR. *See* WALSHE K, **770**
O'MORAIN C. *See* BATE CM, **968**; O'RIORDAN T, **999**
OPOLON P. *See* CADRANEL JF, **483**
Opsonins, IgA and saccharomyces, protracted enteric cryptosporidial infection in selective deficiencies of *(Case report)*, **714**
Oral epithelial cells from aphthous ulcer patients, effector cells responsible for the in vitro cytotoxicity of blood leucocytes for, **294**
O'RIORDAN T, MATHAI E, TOBIN E, MCKENNA D, KEANE C, SWEENEY E, O'MORAIN C: Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate, **999**
Orocaecal transit time in health and disease *(Leading article)*, **250**
ORTIZ A. *See* PARRILLA P, **964**
Osler's disease is not a telangiectasia but a tumour *(Letter)*, **242**
Osmotic pump for delivery of tracer substances or other materials to the colon, **106**
Osteoporosis and skeletal fractures in chronic liver disease, **82**
OTTONELLO L. *See* DALLEGRI F, **184**
OUT MMJ. *See* COENE PPLO, **913**
Oxygen free radicals in acute pancreatitis of the rat, **1138**
metabolites, reactive, in experimental colitis, **786**
metabolites, toxic: production by circulating phagocytic cells in inflammatory bowel disease, **187**
saturation. *See* Arterial oxygen saturation

PACE F, SANGALETTI O, BIANCHI PORRO G: Daytime reduction of gastro-oesophageal reflux after healing of oesophagitis and its value as an indicator of favourable response to maintenance treatment, **1025**
Paf-acether synthesis in *H pylori*, **1242**
Pain, morphine induced, and rises in liver enzymes after cholecystectomy: sympathetic activation? **217**
PAINTER DM. *See* MCDONALD JA, **725**
PALMER KR. *See* GRANT HW, **997**; WILLIAMS AJK, **1082**
Pancreas, ultrasonically guided histological and cytological fine needle biopsies of; reliability and reproducibility of diagnoses, **930**
Pancreatic cancer *(Leading article)*, **494**
carcinoma with polyarthritis, fat necrosis, and high serum lipase and trypsin activity, **953**
duct abnormalities in gall stone disease: ERCP study, **1073**
enzyme secretion, influence of treatment with pancreatic extracts on *(Letter)*, **243**
function in Crohn's disease, **1076**
function test: caerulein induced plasma amino acid decrease, **926**
insufficiency, exocrine, monitoring enzyme replacement treatment in, using cholesteryl octanoate breath test, **1324**
juice, ethanol in, after oral and intravenous administration, **1411**
pseudocyst causing portal vein thrombosis and pancreatico-pleural fistula *(Case report)*, **561**
secretory trypsin inhibitor in gastrointestinal mucosa and gastric juice, **1318**
Pancreaticobiliary ductal union, **1144**
Pancreatitis, acute, prediction of severity of *(Letter)*, **1419**
after sphincter of Oddi manometry, **821**
chronic, pathogenesis of *(Leading article)*, **629**
induced by taurocholate, therapeutic effect of peritoneal lavage on, improved by camostate (FOY-305), **934**
PAONE FM. *See* CUCCHIARA S, **21**, **129**
PAPACHRYSOSTOMOU M. *See* BINNIE NR, **1051**
Papillotomy, needle knife, **905**
Paracetamol overdose, severe thrombocytopenia after *(Case report)*, **1159**
PARENTE F. *See* BIANCHI PORRO G, **397**
PARK K, BLESSING K, KERR K, CHETTY U, GILMOUR H: Goblet cell carcinoid of the appendix, **322**, *(Letter)*, **840**
PARKIN J. *See* JACYNA MR, **714**
PARRATT D. *See* MCKENZIE H, **536**
PARRILLA P, ORTIZ A, MARTINEZ DE HARO LF, AGUAYO JL, RAMIREZ P: Evaluation of the magnitude of gastro-oesophageal reflux in Barrett's oesophagus, **964**
PARRILLI G. *See* PIGNATA C, **879**
PASCAL JP. *See* CALES P, **1298**
PASSARETTI S. *See* GUSLANDI M, **481**; TESTONI PA, **286**
PATEL N. *See* PRIMROSE JN, **1088**
PATHAK K. *See* DILL S, **1237**
PATRONE F. *See* DALLEGRI F, **184**
PAULLEY JW: Why do patients with ulcerative colitis relapse? *(Letters)*, **959**, **1419**
PAYNE-JAMES JJ, MISIEWICZ JJ, SILK D: Palliation of malignant dysphagia *(Letter)*, **1161**
——, SILK DBA: Gastroenterologists and nutritional support *(Letter)*, **483**
——, ——: Use of elemental diets in the treatment of Crohn's disease by gastroenterologists *(Letter)*, **1424**
——. *See also* DILL S, **1237**
PAZZI P, TREVISANI L, SARTORI S, SIGHINOLFI D, ALVISI V: Diabetes and cholithiasis *(Letter)*, **1422**
PEARSON JCG. *See* OLIVER SE, **750**
PEARSON M. *See* TEAHON K, **1133**
PELLIER P. *See* FLOURIE B, **684**
PENA AS. *See* APARICIO-PAGES MN, **1030**; WETERMAN IT, **1387**
PENNINGTON CR. *See* MCKENZIE H, **536**
Peptic injury of oesophagus in rabbits reduced by bismuth subsalicylate, **11**
ulcer and non-ulcer dyspepsia, *H pylori* and gastritis in: ethnic differences in Singapore, **850**
ulcer haemorrhage, massive, trial of heat probe thermocoagulation and pure alcohol injection, **753**
ulcer in India *(Letter)*, **123**
ulcer therapy, some possible pathological consequences of *(Letter)*, **243**
ulcer, towards a true prevalence of: Sorreisa gastrointestinal disorder study, **989**
Peptide. *See* Dodecapeptide
PEREZ J. *See* VIDAL F, **707**
Peritoneal lavage, therapeutic effect on taurocholate induced pancreatitis improved by camostate (FOY-305), **934**
macrophages and healing colon anastomosis in the rat, eicosanoid profile of, **807**
Peritonitis, tuberculous, diagnosed by peritoneoscopy and biopsy over a five year period, symptoms and investigative findings in 145 patients, **1130**
Pernicious anaemia, absence of a gastrin inhibitory factor in the IgG fraction of serum from patients with, **871**
anaemia, development of gastric dysplasia in, follow up study, **1105**
PERSSON P-G, AHLBOM A, HELLERS G: Inflammatory bowel disease and tobacco smoke – a case-control study, **1377**
——. *See* LEIJONMARCK CE, **329**
PETER P. *See* BLUM AL, **825**
PETERS TJ. *See* BANERJEE AK, **1358**; MARSH MN, **32**; PREEDY VR, **305**
PETERSEN HD. *See* RUNE SJ, **151**
Pethidine. *See* Midazolam/pethidine
PETTENGELL KE. *See* MANOHAR A, **1130**
PEVELER RC. *See* FAIRBURN CG, **1220**
Peyer's patches, involvement of M cells in the bacterial invasion of, **1011**
PEZZILLI R. *See* GULLO L, **926**
PFEIFFER A. *See* SAUTER G, **1041**
PFLEIDERER T. *See* BLUM AL, **825**
Ph *See* Gastric; Gastrointestinal intraluminal; Intragastric; Oesophageal
Phagocytic cells, circulating, in inflammatory bowel disease, toxic oxygen metabolite production by, **187**
PHILLIPS S: Sir FA Jones at 80, **491**
PHILLIPS SF. *See* KAMATH PS, **443**; TALLEY NJ, **54**, **77**
Phosphorus-31 magnetic resonance spectroscopy in a study of human liver disease, **463**
PIAZZI L. *See* DOBRILLA G, **355**
PIESSENS J. *See* GHILLEBERT G, **738**
PIGNATA C, BUDILLON G, MONACO G, NANI E, CUOMO R, PARRILLI G, CICCIMARRA F: Jejunal bacterial overgrowth and intestinal permeability in children with immunodeficiency syndromes, **879**
PINCHING AJ. *See* KITCHEN VS, **1223**
PINHO A. *See* SILVA S, **1097**
PINTO B. *See* VIDAL F, **707**
PLAS J: Randomised, double blind comparison of omeprazole and cimetidine in the treatment of symptomatic gastric ulcer *(Letter)*, **483**
——, VAN WILDER PH: Ranitidine nocte v ranitidine mane and nocte *(Letter)*, **242**
Platelet aggregating factor. *See* Paf
PLAYFORD RJ, MATTHEWS CH, CAMPBELL MJ, DELVES HT, HLA KK, HODGSON HJF, CALAM J: Bismuth induced encephalopathy caused by tripotassium dicitrato bismuthate in a patient with chronic renal failure *(Case report)*, **359**
PLAYFORD RJ. *See also* FREEMAN TC, **1318**
POL B. *See* BOURLIERE M, **949**
POLAK JM. *See* COUPE M, **144**
Polyarthritis, fat necrosis, and high serum lipase and trypsin activity complicating pancreatic carcinoma, **953**
POLYDOROU AA. *See* DOWSETT JF, **905**
Polyethylene glycol 400 intestinal permeability is regulated by endogenous and exogenous prostanoids. Influence of non-steroidal anti-inflammatory drugs, **417**
Porphyria cutanea tarda and haemochromatosis: a family study, **719**
Portal hypertension in chronic hepatitis: relationship to morphological changes, **339**

vein thrombosis and pancreatico-pleural fistula caused by pancreatic pseudocyst *(Case report)*, **561**
venous flow, effect of secretin on, **1306**
venous obstruction, extrahepatic, sclerotherapy in, **213**
POSEN S. *See* DIAMOND T, **82**
Postganglionic nerve stimulation in oesophageal achalasia: in vitro study, **17**
POSTON GJ. *See* GRACE PA, **571**
Postvagotomy diarrhoea: is there a place for surgical management? *(Leading article)*, **245**
Potassium concentration at the mucosal surface of the proximal and distal colon of guinea pig, factors affecting, **64**
Pouch, development of cancer in *(Case report)*, **473**
Pouchitis: inflammation in ileal reservoirs *(Leading article)*, **247**
POULSEN SS. *See* RASMUSSEN TN, **92**
POULTER L. *See* FREEMAN TC, **1318**
POULTER LW. *See* SPITERI MA, **208**
POUNDER RE. *See* SMITH JTL, **291**, **522**, **871**, **1087**
POYNTER D: Some possible pathological consequences of peptic ulcer therapy *(Letter)*, **243**
Pravastatin: effect on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia, **348**
PREEDY VR, PETERS TJ: Protein synthesis of muscle fractions from the small intestine in alcohol fed rats, **305**
Pregnancy after liver transplantation, **337**
PRICE AB. *See* DE DOMBAL FT, **115**
PRICE YE. *See* THOMPSON EM, **406**
PRIDDLE JD. *See* MANTZARIS GJ, **668**
PRIMROSE JN, NAIK KS, BLACKETT RL, KING RFG, HOLMFIELD JHM, LAGOPOLOUS M, JOHNSTON D: Is antral gastrin important in the resistance of duodenal ulcers to H_2 receptor antagonists or in recurrent ulceration after highly selective vagotomy? **763**
PRIMROSE JN, PATEL N, ROGERS MR: Inhibition of nocturnal acidity *(Letter)*, **1088**
PRIOR A, COLGAN SM, WHORWELL PJ: Changes in rectal sensitivity after hypnotherapy in patients with irritable bowel syndrome, **896**
——, MAXTON DG, WHORWELL PJ: Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects, **458**
Procoagulant activity in gastroenterology *(Progress report)*, **239**
Prostaglandins stimulating glycoprotein and protein synthesis in isolated pig gastric mucosal cells, **412**
Prostanoids, endogenous and exogenous, in the regulation of polyethylene glycol 400 intestinal permeability. Influence of non-steroidal anti-inflammatory drugs, **417**
Protein and glycoprotein synthesis in isolated pig gastric mucosal cells stimulated by prostaglandins, **412**
C deficiency, hereditary, presenting as acute Budd-Chiari syndrome with hepatic failure and inferior vana caval obstruction, **949**
digestion and metabolism in animal models, effects of lactulose and lactitol on, **1403**
40 kDa. *See* Colonic extract
synthesis of muscle fractions from small intestine in alcohol fed rats, **305**
Proteins, binding B_{12}, **59**
binding to laminin in cell membranes of a human colon adenocarcinoma cell line, identification of, **70**
Sn-Protoporphyrin, a haeme oxygenase inhibitor, in patients with primary biliary cirrhosis and idiopathic haemochromatosis, **899**
PROUSE P. *See* BJARNASON I, **777**
Pruritus in chronic cholestatic liver disease: raised histamine concentrations, **96**
Psychogenic vomiting, **526**
Pudendo-anal reflex, use of, in neurogenic faecal incontinence, **1051**
Pulmonary sarcoidosis and immunological features of lung lavage cells from primary biliary cirrhosis patients, **208**
PYE G, EVANS DF, LEDINGHAM S, HARDCASTLE JD: Gastrointestinal intraluminal pH in normal subjects and those with colorectal adenoma or carcinoma, **1355**
PYORALA K. *See* LAAKSO M, **344**
Pyrogastrone and cimetidine in reflex oesophagitis, controlled trial of *(Clinical trial)*, **351**

QUINN C. *See* FREEMAN TC, **1318**
QUIRKE P. *See* LANSDOWN M, **977**

RACHMILEWITZ D. *See* LIGUMSKY M, **686**
RADDA GK. *See* OBERHAENSLI R, **463**
RADEMACHER T. *See* DUBE R, **431**
Radioactive gastrointestinal marker in a study of ileal function, **1120**
Radiotherapy: what does it add to survival over endoscopic intubation alone in inoperable squamous cell cancer? **750**
RAFIQ ALI M. *See* MORRIS A, **139**
RAJAGOPALAN B. *See* OBERHAENSLI R, **463**
RAJWANSHI A. *See* KOCHHAR R, **334**
RAMAGE JK, MILLER ARO, CLARKE PD: Acute diarrhoea in expatriates in Bangladesh *(Letter)*, **123**
RAMBAUD JC: Short bowel syndrome and somatostatin 201-995 *(Letter)*, **124**
——. *See also* COLOMBEL JF, **1345**; DENIZOT Y, **1242**; FLOURIE B, **684**
RAMBOW A. *See* STARITZ M, **222**
RAMESH GN. *See* CHAWLA YK, **213**
RAMIREZ P. *See* PARILLA P, **964**
Ranitidine and high dose cimetidine, omeprazole in erosive oesophagitis refractory to, **745**
and omeprazole in duodenal or gastric ulcer, comparison of: multicentre trial, **653**
nocte v mane and nocte *(Letter)*, **242**
RANNEM T. *See* HEGNHOJ J, **1076**
RAO KJM, BLAKE H, THEODOSSI A: Use of a modified angioplasty balloon catheter in the dilatation of tight biliary strictures, **565**
RAOUF A. *See* BARR H, **252**, **1161**
RASCHER W. *See* TULASSAY T, **1419**
RASENACK U. *See* BLUM AL, **825**
RASK-MADSEN J. *See* STAERK LAURSEN L, **1271**
RASMUSSEN TN, JORGENSEN PE, ALMDAL T, POULSEN SS, OLSEN PS: Effect of gastrin on liver regeneration after partial hepatectomy in rats, **92**
RATCLIFFE B. *See* BIRD SP, **1403**
RATHBONE BJ. *See* HESSEY SJ, **134**
RAUNDAHL U. *See* TOTTRUP A, **17**
RAVAUD A. *See* CALES P, **1298**
READ NW. *See* BROWN NJ, **1126**; BROWN SR, **450**; HIGHAM SE, **435**; HOUGHTON LA, **1226**; SEPPLE CP, **158**; SUN WM, **1056**
Rectal blood flow, effect of ulcerative colitis and smoking on, **1021**
masses, fine needle aspiration cytology of, **334**
mucosal dysplasia in Crohn's disease, **1382**
sensation and anal function in normal subjects and in patients with faecal incontinence, **1056**
sensitivity in irritable bowel syndrome, changes in, after hypnotherapy, **896**
Rectosigmoid cancer, endoscopic Nd:YAG laser treatment of, **812**
Rectum, pressure-volume relations in irritable bowel syndrome, inter- and intraindividual variation, **1062**
reduced filling of, and motor neuropathy, in chronic intractable constipation, **1284**
Rectum. *See also* Colorectal cancer
REED WD. *See* JEFFREY GP, **698**
REES H. *See* COUPE M, **144**
REES WDW. *See* SHORROCK CJ, **26**, **958**
Reflux. *See* Acid; Gastro-oesophageal; Oesophagitis
Rehydration solutions, oral, using human whole gut perfusion, efficacy of, **1115**
REICHEN J. *See* COTTING J, **918**
Renal failure, chronic, bismuth induced encephalopathy caused by tripotassium dicitrato bismuthate in a patient with *(Case report)*, **359**
RENNIE MJ. *See* DILL S, **1237**
REPPER JA. *See* JONES RH, **401**
Reticulin antibodies, IgA class, of human subtype, in gluten sensitive enteropathy *(Letter)*, **585**
RHODES J. *See* CLEMENTS D, **1333**; SRIVASTAVA ED, **1021**
RHODES JM: Colonic mucus and colitis – author's reply *(Letter)*, **730**
RIAD MA. *See* BARTON JR, **378**
RICHARDSON A. *See* BROWN NJ, **1126**
RICHARDSON PDI. *See* BATE CM, **968**
RICHART C. *See* VIDAL F, **707**
RIECKEN EO. *See* GRUTZKAU A, **1011**; STALLMACH A, **70**
RIERMESMA RR. *See* GRANT HW, **997**
RILEY SA, MANI V, GOODMAN MJ, LUCAS S: Why do patients with ulcerative colitis relapse? **179** *(Letter)*, **959**
RITCHIE JK. *See* LENNARD-JONES JE, **800**
ROBERTS-THOMSON IC, JONSSON JR, FREWIN DB, COATES GC: Sympathetic activation: a mechanism for morphine induced pain and rises in liver enzymes after cholecystectomy? **217**
ROBERTS-THOMSON PJ, SHEPHERD K: Low molecular weight IgM in primary biliary cirrhosis, **88**
ROBERTSON CS. *See* OLIVER SE, **750**
ROBERTSON DAF. *See* AYRES RCS, **722**
ROBINSON D. *See* STEADMAN C, **845**
ROBINSON P. *See* ALBERT V, **311**
ROCHE J. *See* DIAMOND T, **82**
RODE J. *See* ARMBRECHT U, **1195**; JENNINGS PE, **558**
RODRIGUEZ R. *See* VILASECA J, **539**
ROEHMEL J. *See* MERKI HS, **148**
ROELS H. *See* CUVELIER C, **545**
ROGERS MR. *See* PRIMROSE JN, **1088**
ROHNER A. *See* MOREL P, **875**
ROHNER HG. *See* BLUM AL, **825**
ROLA FH. *See* XAVIER-NETO J, **1006**
ROLNY P, ANDERBERG B, IHSE I, LINDSTROM E, OLAISON G, ARVILL A: Pancreatitis after sphincter of Oddi manometry, **821**
ROLSTON DDK, ZINZUVADIA SN, MATHAN VI: Evaluation of the efficacy of oral rehydration solutions using human whole gut perfusion, **1115**
——. *See also* WATSON AJM, **170**
RONCHI G. *See* VECCHI M, **482**
ROOK GAW. *See* DUBE R, **431**
ROSE DSC. *See* GOLDIN RD, **554**

ROWLAND R. *See* CUMMINS AG, **317**
RUMESSEN JJ, HAMBERG O, GUDMAND-HOYER E: Interval sampling of end-expiratory hydrogen concentrations to quantify carbohydrate malabsorption by means of lactulose standards, **37**
RUMSEY RDE. *See* BROWN NJ, **1126**
RUNE SJ, LINDE J, BONNEVIE O, PETERSEN HD, BENDTSEN F, WANDALL JH, GLUUD C, ERIKSEN J, SKOVBJERG H, VILIEN M, OLESEN M, LARSEN S, SCHLICHTING P, GORMSEN M, WULFF HR, VADSTRUP S, VESTERGAARD BF: Acyclovir in the prevention of duodenal ulcer recurrence, **151**
RUSSELL MAH. *See* SRIVASTAVA ED, **1021**
RUSSELL RCG. *See* DOWSETT JF, **905**
RUSSELL RI. *See* MCKINLAY AW, **940**
RUTGEERTS P. *See* HIELE M, **175**

Saccharomyces and IgA opsonin deficiencies, selective, protracted enteric cryptosporidial infection in *(Case report)*, **714**
Saccharomyces cerevisiae (baker's and brewer's yeast), selected strains of, antibody to, in Crohn's disease, **536**
SACHS JA. *See* CAFFREY C, **663**
SACRE L. *See* VANDENPLAS Y, **374**
SAGHER FA, DODGE JA, MOORE R, MCMASTER C, MCCAUGHEY G: Modulation of fluid absorption and the secretory response of rat jejunum to cholera toxin by dietary fat, **1256**
SAHLIN S, AHLBERG J, EINARSSON K, HENRIKSSON R, DANIELSSON A: Quantitative ultrastructural studies of gall bladder epithelium in gall stone free subjects and patients with gall stones, **100**
SAIGENJI K. *See* OKADA M, **758**
SAINI N. *See* TAY HP, **11**
SAKAI H. *See* SAKU T, **1250**
SAKAMOTO K. *See* OKADA M, **758**
SAKHUJA V, GUPTA KL, BHASIN DK, MALIK N, CHUGH KS: Takayasu's arteritis associated with idiopathic ulcerative colitis, **831**
SAKU T, SAKAI H, TSUDA N, OKABE H, KATO Y, YAMAMOTO K: Cathepsins D and E in normal, metaplastic, dysplastic, and carcinomatous gastric tissue: an immunohistochemical study, **1250**
SAKURAI A. *See* TARAO K, **702**
SALAS A. *See* VILASECA J, **539**
SALIM B. *See* CLOAREC D, **300**
SALMON PR. *See* DOWSETT JF, **905**
SANGALETTI O. *See* BIANCHI PORRO G, **397**; PACE F, **1025**
SANWALD R. *See* BLUM AL, **825**
Sarcoidosis. *See* Pulmonary sarcoidosis
SARLES H, BERNARD JP, GULLO L: Pathogenesis of chronic pancreatitis *(Leading article)*, **629**
SARTORI S. *See* PAZZI P, **1422**
SAUTER G, NERLICH A, SPENGLER U, KOPP R, PFEIFFER A: Low diacylglycerol values in colonic adenomas and colorectal cancer, **1041**
SAVARINO V, MELA GS, CELLE G: Influence of time of dinner on nocturnal gastric pH *(Letter)*, **364**
SAVARINO V, MELA G, SUMBERAZ A, CELLE G: Omeprazole in H_2 blocker non-responders *(Letter)*, **584**
SAVARINO V. *See also* MELA GS, **1087**
SAVILAHTI E. *See* VERKASALO MA, **422**
SAWYERR AM. *See* BLAKE JC, **556**
SBOLLI G, FORNARI F, CIVARDI G, DI STASI M, CAVANNA L, BUSCARINI E, BUSCARINI L: Role of ultrasound guided fine needle aspiration biopsy in the diagnosis of hepatocellular carcinoma, **1303**
SCHAAP HM, SMOUT AJPM, AKKERMANS LMA: Myoelectrical activity of the Billroth II gastric remnant, **984**
SCHEUER PJ. *See* BLAKE JC, **556**; VAN LEEUWEN DJ, **339**
Schistosomal colonic disease, **439**
SCHLICHTING P. *See* RUNE SJ, **151**
SCHNEIDER C. *See* KISS A, **259**
SCHOENBERG MH, BUCHLER M, GASPAR M, STINNER A, YOUNES M, MELZNER I, BULTMANN B, BEGER HG: Oxygen free radicals in acute pancreatitis of the rat, **1138**
SCHULMAN ES. *See* GITTLEN SD, **96**
SCHUPPAN D. *See* STALLMACH A, **70**
SCHWEITZER EJ. *See* TAY HP, **11**
Scintigraphic assessment of endoscopic sphincterotomy in sphincter of Oddi dysfunction, **231**
Sclerotherapy in extrahepatic portal venous obstruction, **213**
Scotland and England, dyspepsia in, **401**
SCOTT B: Endoscopic demands in the 90's *(Leading article)*, **125**
SCOTT BB. *See* JENKINS D, **426**
SCRIMGEOUR CM. *See* DILL S, **1237**
Secretin, effect on portal venous flow, **1306**
SEDGHI S. *See* KESHAVARZIAN A, **786**
SEGAL I. *See* GIBSON GR, **679**
SEHESTED M. *See* GLENTHOJ A, **930**
SEIDENSTICKER F. *See* LEONHARDT U, **934**
SELBY PJ. *See* JONES A, **938**
SELDENRIJK CA, DREXHAGE HA, MEUWISSEN SGM, MEIJER CJLM: T-cellular immune reactions (in macrophage inhibition factor assay) against *Mycobacterium paratuberculosis, M kansasii, M tuberculosis, M avium* in patients with chronic inflammatory bowel disease, **529**
SEPPLE CP, READ NW: Effect of prefeeding lipid on food intake and satiety in man, **158**
SEVESTRE H. *See* FIEVET P, **361**
SEWING K-FR. *See* HEIM H-K, **412**
SEYMOUR DG, ELDER GH, FRYER A, JACOBS A, WILLIAMS GT: Porphyria cutanea tarda and haemochromatosis: a family study, **719**
SHAH HS. *See* TAKAHASI F, **1016**
SHAW J. *See* MARSH MN, **32**
SHEARMAN DJC. *See* CUMMINS AG, **317**, **960**
SHEPHERD HA. *See* DEHN TCB, **509**
SHEPHERD K. *See* ROBERTS-THOMSON PJ, **88**
SHER-I-KASHMIR. *See* KHUROO MS, **123**
SHERLOCK DJ, SUAREZ V, GRAY JG: Stomal adenocarcinoma in Crohn's disease *(Case report)*, **1329**
SHERLOCK S: Vasodilatation associated with hepatocellular disease: relation to functional organ failure *(Leading article)*, **365**
——: *See also* SPITERI MA, **208**; VAN LEEUWEN DJ, **339**
Shields, Robert, short biography of, **1085**
SHINDO K. *See* TARAO K, **702**
Shockwaves. *See* Extracorporeal shockwave (s)
SHORROCK CJ, GARNER A, HUNTER AH, CRAMPTON JR, REES WDW: Effect of bismuth subcitrate and sucralfate on rat duodenal and human gastric bicarbonate secretion in vivo, **26**, *(Letter)*, **958**
Short bowel syndrome and somatostatin 201-995 *(Letter)*, **124**
SHORTER RG. *See* TALLEY NJ, **54**
SIGHINOLFI D. *See* PAZZI P, **1422**
SILK DBA. *See* PAYNE-JAMES JJ, **483**, **1161**, **1424**
SILVA S, FILIPE MI, PINHO A: Variants of intestinal metaplasia in the evolution of chronic atrophic gastritis and gastric ulcer. A follow up study, **1097**
SIMJEE AE. *See* MANOHAR A, **1130**
SIMON PL. *See* LIGUMSKY M, **686**
Singapore: *H pylori* and gastritis in peptic ulcer and non-ulcer dyspepsia, **850**
SINGER MV, NIEBEL W, BECKER S: Coeliac ganglionectomy *(Letter)*, **1335**
SITUNAYAKE RD, CRUMP BJ, THURNHAM DI, DAVIES JA, GEARTY J, DAVIS M: Lipid peroxidation and hepatic antioxidants in alcoholic liver disease, **1311**
SJODAHL R. *See* OLAISON G, **326**
Skeletal fractures and osteoporosis in chronic liver disease, **82**
SKOVBJERG H. *See* RUNE SJ, **151**
SLOAN JM. *See* COLLINS JSA, **858**
SMETHURST P. *See* BJARNASON I, **777**
SMITH AN. *See* BINNIE NR, **1051**
SMITH CL. *See* AYRES RCS, **722**
SMITH JA, GRIFFIN M, MIREYLEES SE, LONG RG: Effect of vasoactive intestinal peptide on cyclic adenosine monophosphate production in enterocytes isolated from human duodenal biopsy specimens, **1350**
SMITH JAR: Goblet cell carcinoid of the appendix *(Letter)*, **840**
SMITH JTL, GARNER A, HAMPSON SE, POUNDER RE: Absence of a gastrin inhibitory factor in the IgG fraction of serum from patients with pernicious anaemia, **871**
SMITH JTL, POUNDER RE: Sufotidine 600mg bd virtually eliminates 24 hour intragastric acidity in duodenal ulcer subjects, **291**, *(Letter)*, **1087**
SMITH JTL, POUNDER RE, NWOKOLO CU, LANZON-MILLER S, EVANS DG, GRAHAM DY, EVANS DJ: Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with *Helicobacter pylori*, **522**
SMITH PG. *See* FELLOWS IW, **728**
SMITH RB. *See* HOLMAN RAE, **504**
SMITH T, BJARNASON I: Experience with a gastrointestinal marker (^{51} CrCl$_3$) in a combined study of ileal function using ^{75}SeHCAT and ^{58}CoB$_{12}$ measured by whole body counting, **1120**
Smokers and patients with epithelial head and neck tumours, mucosal immunodeficiency in, **378**
Smoking and acid reflux, **4**
and ulcerative colitis, effect on rectal blood flow, **1021**; *See also* Tobacco smoke
SMOUT AJPM. *See* SCHAAP HM, **984**
SMS 201-995. *See* Somatostatin analogue
SNOOK J: Are the inflammatory bowel diseases autoimmune disorders? *(Leading article)*, **961**
SOBALA G. *See* HESSEY SJ, **134**
SOBHANI I. *See* DENIZOT Y, **1242**
SOBIRK H. *See* HEGNHOJ J, **1076**
Sodium/proton exchange, defective, in jejunal brush border membrane, in association with lethal familial protracted diarrhoea, **1156**
transport, colonic, development in early childhood and regulation by aldosterone, **194**
SOFTLEY A. *See* DE DOMBAL FT, **115**
SOKAL M. *See* OLIVER SE, **750**
Somatostatin analogue SMS 201-995 and short bowel syndrome *(Letter)*, **124**
SOMMERS SC. *See* KORELITZ BI, **1382**
SONNENBERG A: Occupational distribution of inflammatory bowel disease among German employees, **1037**
Sorreisa gastrointestinal disorder study, **989**
Spectroscopy. *See* Phosphorus-31
SPEEKENBRINK ABJ. *See* WALSHE K, **770**
SPJELDNAES N. *See* NOLTE H, **791**
SPENCER J. *See* HESSEY SJ, **134**, VINEY J, **844**

SPENGLER U. *See* SAUTER G, **1041**
Sphincter of Oddi dysfunction, clinical and scintigraphic assessment of endoscopic spincterotomy in, **231**
of Oddi manometry, pancreatitis after, **821**
SPITERI MA, JOHNSON M, EPSTEIN O, SHERLOCK S, CLARKE SW, POULTER LW: Immunological features of lung lavage cells from patients with primary biliary cirrhosis may reflect those seen in pulmonary sarcoidosis, **208**
Spondylarthropathy, seronegative, HLA-DR expression by ileal epithelial cells in, **545**
SPRINGER CJ. *See* COUPE M, **144**
SRAI SKS. *See* CHESTA J, **660**
Sri Lanka, oesophageal carcinoma in *(Letter)*, **242**
SRIVASTAVA ED, RUSSELL MAH, FEYERABEND C, RHODES J: Effect of ulcerative colitis and smoking on rectal blood flow, **1021**
STACHER G. *See* KISS A, **259**
STACHER-JANOTTA G. *See* KISS A, **259**
STAERK LAURSEN L, STOKHOLM M, BUKHAVE K, RASK-MADSEN J, LAURITSEN K: Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion, **1271**
STAIANO A. *See* CUCCHIARA S, **21**, **129**
STAKKEVOLD PA. *See* BERNERSEN B, **989**
STALDER GA. *See* BLUM AL, **825**
STALLMACH A, SCHUPPAN D, DAX J, HANSKI C, RIECKEN EO: Identification of laminin binding proteins in cell membranes of a human colon adenocarcinoma cell line, **70**
STANKIEWICZ H. *See* LIGUMSKY M, **1416**
STANLEY DP. *See* CUMMINS AG, **317**
Starch formulations: $^{13}CO_2$ breath test to measure hydrolysis in healthy subjects, **175**
STARITZ M, RAMBOW A, GROSSE A, HURST A, FLOTH A, MILDENBERGER P, GOEBEL M, JUNGINGER TH, HOHENFELLNER R, THELEN M, MEYER ZUM BUSCHENFELDE K and H: Electromagnetically generated extracorporeal shockwaves for fragmentation of extra- and intrahepatic bile duct stones: indications, success and problems during a 15 months clinical experience, **222**
Starvation induces ileal hypersecretion in rat, **162**
induces jejunal hypersecretion in rat, **43**
STEADMAN C, KERLIN P, CRIMMINS F, BELL J, ROBINSON D, DORRINGTON L, MCINTYRE A: Spontaneous intramural rupture of the oesophagus, **845**
STEELE J. *See* DUBE R, **431**
STEIN AG. *See* DANESHMEND TK, **514**
STEINER-MITTELBACH G. *See* KISS A, **259**
STEINRINGER H. *See* KISS A, **259**
STERN H, WALFISCH S, MULLEN B, MCLEOD R, COHEN Z: Cancer in an ileoanal reservoir: a new late complication? *(Case report)*, **473**
STIEL D. *See* DIAMOND T, **82**
STINNER A. *See* SCHOENBERG MH, **1138**
STOCKBRUGGER RW. *See* ARMBRECHT U, **1105**
STOCKMANN F. *See* LEONHARDT U, **934**
STOKHOLM M. *See* STAERK LAURSEN L, **1271**
Stomach, human, histamine containing cells in, **383**
human, tightly spiral shaped bacteria in, **139**
to caecum transit time, delayed, in the diabetic rat. Possible role of hyperglucagonaemia, **660**
to caecum transit. *See also* Ileal brake
See also Gastric; Gastritis
Stomal adenocarcinoma in Crohn's disease *(Case report)*, **1329**
STRAUME B. *See* BERNERSEN B, **989**
STRONG RW. *See* WALKER NI, **584**
Strongyloides stercoralis associated with a bleeding gastric ulcer *(Case report)*, **1414**
STUDLEY JGN, LINEHAN IP, OGILVIE AL, DOWLING BL: Swallowed button batteries: is there a consensus on management? **867**
SUAREZ V. *See* SHERLOCK DJ, **1329**
Sucralfate and bismuth subcitrate, effect on rat duodenal and human gastric bicarbonate secretion in vivo, **26**, *(Letter)*, **958**
in treatment and prevention of gastric ulcer *(Clinical trial)*, **825**
Sufotidine 600mg bd virtually eliminates 24 hour intragastric acidity in duodenal ulcer subjects, **291**, *(Letter)*, **1087**
SUGAI M. *See* MAROTTA F, **279**
SUHONEN M. *See* LAAKSO M, **344**
SULE D. *See* KELLER KM, **1156**
Sulphasalazine, 5-aminosalicylic acid, and olsalazine, scavenger effect of *(Letter)*, **730**
inhibition of cell mediated cytotoxicity by, **1030**
SUMBERAZ A. *See* SAVARINO V, **584**
SUN WM, READ NW, MINER PB: Relation between rectal sensation and anal function in normal subjects and patients with faecal incontinence, **1056**
SUNDLER F. *See* LONROTH H, **383**; TIELEMANS Y, **274**
Surgical patients, enteral nitrogen support in, **1277**
SUTHERLAND IH. *See* KANG JY, **850**; WEE A, **1093**
SUZUKI K, MUTO T, MASAKI T, MORIOKA Y: Microspectrophotometric DNA analysis in ulcerative colitis with special reference to its application in diagnosis of carcinoma and dysplasia, **1266**
SWANSON NR. *See* JEFFREY GP, **698**
SWEENEY E. *See* O'RIORDAN T, **999**
SWOBODNIK W. *See* JANOWITZ P, **1407**
Sympathetic activation: mechanism for morphine induced pain and rises in liver enzymes after cholecystectomy? **217**
SZAZ KF. *See* CHACKO A, **106**

T cell number and epithelial HLA class II expression in normal and inflamed human gastric mucosa, **647**
T cells and macrophages from lamina propria, differential expression of CD24 (interleukin-2 receptor) on, in intestinal lesions in Crohn's disease and ulcerative colitis, **1365**
gamma/delta, in the gut epithelium *(Leading article)*, **841**
T-cellular immune reactions against *Mycobacterium paratuberculosis*, *M kansasii*, *M tuberculosis*, *M avium* in chronic inflammatory bowel disease, **529**
TAGESSON C. *See* OLAISON G, **325**
TAINIO V-M. *See* VERKASALO MA, **422**
TAKAHASI F, SHAH HS, WISE LS, DAS KM: Circulating antibodies against human colonic extract enriched with a 40 kDa protein in patients with ulcerative colitis, **1016**
Takayasu's arteritis associated with idiopathic ulcerative colitis *(Case report)*, **831**
TALLEY NJ, PHILLIPS SF, MELTON LJ, MULVIHILL C, WILTGEN C, ZINSMEISTER AR: Diagnostic value of the Manning criteria in irritable bowel syndrome, **77**
——: SHORTER RG, PHILLIPS SF, ZINSMEISTER AR: Eosinophilic gastroenteritis: a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues, **54**
TANAKA K. *See* OKADA M, **758**
TANNER WA. *See* DARZI A, **1110**
TARAO K, IKEDA T, HAYASHI K, SAKURAI A, OKADA T, ITO T, KARUBE H, NOMOTO T, MIZUNO T, SHINDO K: Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy, **702**
TASMAN-JONES C. *See* THOMSEN LL, **1230**
TATSUTA M, IISHI H, OKUDA S: Gastric emptying in patients with fundal gastritis and gastric cancer, **767**
——: ISHIKAWA H, IISHI H, OKUDA S, YOKOTA Y: Reduction of gastric ulcer recurrence after suppression of *Helicobacter pylori* by cefixime, **973**
Taurocholate induced pancreatitis, camostate improves the therapeutic effect of peritoneal lavage on, **934**
TAY HH. *See* KANG JY, **476**, **850**
TAY HP, CHAPARALA RC, HARMON JW, HUESKEN J, SAINI N, HAKKI FZ, SCHWEITZER EJ: Bismuth subsalicylate reduces peptic injury of the oesophagus in rabbits, **11**
TAYLOR CJ. *See* BAXTER P, **817**
TAYLOR DJ. *See* OBERHAENSLIE R, **463**
TEAHON K, BJARNASON I, PEARSON M, LEVI AJ: Ten years' experience with an elemental diet in the management of Crohn's disease, **1133**
TEDESCHI A. *See* BARRESI G, **482**
Telangiectasia, Osler's disease is not a *(Letter)*, **242**
TEMPERLEY JM. *See* BATE CM, **968**
TESTONI PA, BAGNOLO F, FANTI L, PASSARETTI S, TITTOBELLO A: Longterm oral cisapride improves interdigestive antroduodenal motility in dyspeptic patients, **286**
THELEN M. *See* STARITZ M, **222**
THEODOSSI A. *See* RAO KJM, **565**
Thermocoagulation. *See* Heat probe
THOMAS DW, BAGG J, WALKER DM: Characterisation of the effector cells responsible for the in vitro cytotoxicity of blood leucocytes from aphthous ulcer patients for oral epithelial cells, **294**
THOMAS WM, HARDCASTLE JD: Role of upper gastrointestinal investigations in a screening study for colorectal neoplasia, **1294**
THOMAS Y. *See* DENIZOT Y, **1242**
THOMPSON DG. *See* BATE CM, **968**; KENDALL GPN, **1062**
THOMPSON EM, PRICE YE, WRIGHT NA: Kinetics of enteroendocrine cells with implications for their origin: a study of the cholecystokinin and gastrin subpopulations combining tritiated thymidine labelling with immunocytochemistry in the mouse, **406**
THOMPSON H. *See* DE DOMBAL FT, **115**
THOMPSON M. *See* BARDHAN KD, **745**
THOMSEN L. *See* MORRIS A, **139**
THOMSEN LL, GAVIN JB, TASMAN-JONES C: Relation of *Helicobacter pylori* to the human gastric mucosa in chronic gastritis of the antrum, **1230**
THORNTON JR, LOSOWSKY MS: Severe thrombocytopenia after paracetamol overdose *(Case report)*, **1159**
Thrombocytopenia, severe, after paracetamol overdose *(Case report)*, **1159**
Thromboxane synthetase inhibitors: effect on experimental NSAID enteropathy in the rat, **1358**
THURNHAM DI. *See* SITUNAYAKE RD, **1311**
TI TK. *See* KANG JY, **550**
TIELEMANS Y, AXELSON J, SUNDLER F, WILLEMS G, HAKANSON R: Serum gastrin concentration affects the self replication rate of the enterochromaffin like cells in the rat stomach, **274**
TITTOBELLO A. *See* GUSLANDI M, **481**; TESTONI PA, **286**
TJIVRAS M. *See* ARCHIMANDRITIS AJ, **481**
Tobacco smoke and inflammatory bowel disease, case-control study, **1377**
TOBIN E. *See* O'RIORDAN T, **999**
TODA K. *See* HIBI T, **1371**

TOGHILL PJ. *See* FELLOWS IW, **728**
TOOULI J. *See* WYMAN JB, **639**
TORGANO G. *See* VECCHI M, **482**
TOROK E. *See* KARPATI S, **585**
TORP-PEDERSEN S. *See* GLENTHOJ A, **930**
TORPIER G. *See* COLOMBEL JF, **583**
TORRES J, JENNISCHE E, LANGE S, LONNROTH I: Enterotoxins from *Clostridium difficile*; diarrhoeogenic potency and morphological effects in the rat intestine, **781**
TOTTRUP A, FORMAN A, FUNCH-JENSEN P, RAUNDAHL U, ANDERSSON K-E: Effects of postganglionic nerve stimulation in oesophageal achalasia: an in vitro study, **17**
TOVEY FI, JAYARAJ AP: Peptic ulcer in India *(Letter)*, **123**
Transit. *See* Colonic capacitance and transit; Gastrointestinal; Orocaecal; Stomach to caecum
TREVISANI L. *See* PAZZI P, **1422**
Tripotassium dicitrato bismuthate causing bismuth induced encephalopathy in a patient with chronic renal failure *(Case report)*, **359**
dicitrato bismuthate in non-ulcer dyspepsia: ^{13}C-urea in detection of *H pylori* and monitoring effect, **1237**
Trypsin and lipase activity, high, in serum, fat necrosis and polyarthritis complicating pancreatic carcinoma, **953**
TSAI YT. *See* LIN HJ, **753**
TSUCHIYA M. *See* HIBI T, **1371**
TSUDA N. *See* SAKU T, **1250**
Tuberculosis. *See* Peritonitis
TUCCARI G. *See* BARRESI G, **482**
TULASSAY T, TULASSAY Z, RASCHER W: Effects of albumin infusion in cirrhotic patients *(Letter)*, **1419**
TULASSAY Z. *See* TULASSAY T, **1419**
Tumour necrosis factor, cholestatic jaundice, and chronic liver disease *(Hypothesis)*, **938**
necrosis factor, endotoxin induced: lactulose inhibits production by monocytes in vitro, **198**
Tumours. *See* Head and neck tumours
TURK JL. *See* MITCHELL IC, **674**
TVEDE N. *See* BRYNSKOV J, **795**
TYTGAT GNJ. *See* COENE PPLO, **913**

UDESHI U. *See* MIKE N, **883**
Ulcer(s) *See* Aphthous; Duodenal; Gastric; Peptic
Ulcerative colitis, a potential mechanism for the therapeutic action of 5-aminosalicylic acid in, **184**
colitis and Crohn's disease: differential expression of CD25 (interleukin-2 receptor) on lamina propria T cells and macrophages in intestinal lesions, **1365**
colitis and smoking, effect on rectal blood flow, **1021**
colitis, circulating antibodies against human colonic extract enriched with a 40 kDa protein, **1016**
colitis, epidemiologic study of colectomy rate in, **329**
colitis, extensive, precancer and cancer in: findings among 401 patients over 22 years, **800**
colitis, idiopathic, and associated Takayasu's arteritis *(Case report)*, **831**
colitis: in vitro anticolon antibody production by mucosal or peripheral blood lymphoctes, **1371**
colitis, microspectrophotometric DNA analysis in diagnosis of carcinoma and dysplasia, **1266**
colitis: one disease or two? **426**
colitis patients with normal liver function tests, liver histology and follow up of, **468**
colitis, screening for colorectal cancer in: dubious benefits and high costs *(Leading article)*, **1089**
colitis, why do patients relapse? **179**, *(Letters)*, **959**, **1419**
See also Pouch; Pouchitis
Ultrasound, abdominal, intraoperative *(Leading article)*, **368**
guided biopsies. *See* Fine needle
UMAR HM. *See* DEES A, **1414**
UNWIN BJ. *See* DE DOMBAL FT, **115**
UPADHYAY R. *See* MCKINLAY AW, **940**
Uraemia, gastroduodenal mucosa in: endoscopy, histology and helicobacter-like organisms, **1093**
Urea, 15N labelled, metabolism in the functioning human colon: luminal hydrolysis and mucosal permeability, **454**
synthesis and amino acid clearance increased in a patient with glucagonoma *(Case report)*, **946**
Urease test, one minute *(Letter)*, **840**
Urinary acid excretion, changes in, and gastric acid secretion, relation between, **862**
Ursodeoxycholic acid: effect on hepatic biliary lipid secretion and gall bladder biliary lipid mass in gall stone patients, **226**
acid, effect on nutrition and liver function in cystic fibrosis patients with longstanding cholestasis, **918**

VADSTRUP S. *See* RUNE SJ, **151**
VAERMAN JP. *See* COLOMBAL JF, **1345**
Vagotomy, highly selective, recurrent duodenal ulceration after, is antral gastrin important? **763**
See also Postvagotomy
VAIRA D. *See* DOWSETT JF, **905**
VALLOTTON J-J. *See* BLUM AL, **825**
VALNES K, HUITFELDT HS, BRANDTZAEG P: Relation between T cell number and epithelial HLA class II expression quantified by image analysis in normal and inflamed human gastric mucosa, **647**
VALORI RM: Nutcracker, neurosis, or sampling bias? *(Leading article)*, **736**
VAN BLANKENSTEIN M. *See* HOOGERBRUGGE-VD LINDEN N, **348**
Vancomycin hydrochloride in lactulose resistant chronic hepatic encephalopathy, **702**, *(Letter)*, **702**
VAN DE KAA CA. *See* VAN KLAVEREN RJ, **953**
VANDENPLAS Y, HELVEN R, GOYVAERTS H, SACRE L: Reproducibility of continuous 24 hour oesophageal pH monitoring in infants and children, **374**, *(Letter)*, **1420**
VAN DER HAM AC, KORT WJ, BIJMA AM, ZIJLSTRA FJ, VERMEER MA, JEEKEL J: Eicosanoid profile of healing colon anastomosis and peritoneal macrophages in the rat, **807**
VAN HAELST UJGM. *See* VAN KLAVEREN RJ, **953**
VAN KLAVEREN RJ, DE MULDER PHM, BOERBOOMS AMT, VAN DE KAA CA, VAN HAELST UJGM, WAGENER DJT, HAFKENSCHEID JCM: Pancreatic carcinoma with polyarthritis, fat necrosis, and high serum lipase and trypsin activity, **953**
VAN LEEUWEN DJ, HOWE SC, SCHEUER PJ, SHERLOCK S: Portal hypertension in chronic hepatitis: relationship to morphological changes, **339**
VAN LOON FPL: Acute diarrhoea in expatriates in Bangladesh *(Letter)*, **123**
VANTRAPPEN G. *See* GHILLEBERT G, **738**; HIELE M, **175**
VAN WILDER PH. *See* PLAS J, **242**
Vascular malformations, intracranial, and associated focal nodular hyperplasia of the liver *(Case report)*, **554**
Vasoactive intestinal peptide, effect on cyclic adenosine monophosphate production in enterocytes isolated from human duodenal biopsy specimens, **1350**
Vasodilatation associated with hepatocellular disease: relation to functional organ failure *(Leading article)*, **365**
VECCHI M, TORGANO G, DE FRANCHIS R, AGAPE D, RONCHI G: Lectin binding sites in the jejunal mucosa of patients with gluten sensitive enteropathy *(Reply to Letter)*, **482**
VENTRUCCI M. *See* GULLO L, **926**
VEREBELYI T. *See* VIZI ES, **1046**
VERGANI D. *See* LOBO-YEO A, **690**
VERKASALO MA, ARATO A, SAVILAHTI E, TAINIO V-M: Effect of diet and age on jejunal and circulating lymphocyte subsets in children with coeliac disease: persistence of CD4-8-intraepithelial T cells through treatment, **422**
VERMEER MA. *See* VAN DER HAM AC, **807**
VERSPAGET HW. *See* APARICIO-PAGES MN, **1030**
VERWEIJ J. *See* DEES A, **1414**
VESTERGAARD BF. *See* RUNE SJ, **151**
VEYS E. *See* CUVLIER C, **545**
VIDAL F, PEREZ J, MORANCHO J, PINTO B, RICHART C: Hepatic alcohol dehydrogenase activity in alcoholic subjects with and without liver disease, **707**
VILASECA J, SALAS A, GUARNER F, RODRIGUEZ R, MARTINEZ M, MALAGELADA J-R: Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis, **539**
VILIEN M. *See* RUNE SJ, **151**
VILLA G. *See* MELA GS, **1087**
Villous adenoma of the common hepatic duct: role of ultrasound in management *(Case report)*, **558**
VILSTRUP H. *See* ALMDAL TP, **946**
VINEL JP. *See* CALES P, **1298**
VINER C. *See* JONES A, **938**
VINEY J, MACDONALD TT, SPENCER J: Gamma/delta T cells in the gut epithelium *(Leading article)*, **841**
Vitamin B_{12} binding proteins, **59**
VIZI ES, ZSELI J, KONTOR E, FEHER E, VEREBELYI T: Characteristics of cholinergic neuroeffector transmission of ganglionic and aganglionic colon in Hirschsprung's disease, **1046**
Vomiting, psychogenic: the relation between patterns of vomiting and psychiatric diagnosis, **526**
VON ENGELHARDT W. *See* KUCK-BIERE U, **64**
Von Hippel-Lindau syndrome complicated by carcinoid tumour of the common bile duct *(Case report)*, **728**
VORSTER HH. *See* GIBSON GR, **679**

WAGENER DJT. *See* VAN KLAVEREN RJ, **953**
WAKEFIELD A, COHEN Z, LEVY G: Procoagulant activity in gastroenterology *(Progress report)*, **239**
WALDRON DJ, KUMAR D, HALLAN RI, WINGATE DL, WILLIAMS NS: Evidence for motor neuropathy and reduced filling of the rectum in chronic intractable constipation, **1284**
WALFISCH S. *See* STERN H, **473**
WALIA BNS. *See* CHAWLA YK, **213**
WALKER ARP. *See* GIBSON GR, **679**
WALKER BE. *See* GOODE HF, **694**

WALKER DM. *See* THOMAS DW, **294**
WALKER MM. *See* BARON JH, **242**
WALKER NI, STRONG RW: Epithelial dysplasia in Caroli's disease *(Letter)*, **584**
WALKER RJ. *See* BARR H, **252**, **1161**
WALKER SJ. *See* HARTLEY MN, **500**
WALKER-SMITH JA. *See* CHOY MY, **1365**
WALLIN L. *See* KRUSE-ANDERSEN S, **633**
WALSHE K, HEALY MJ, SPEEKENBRINK ABJ, KEANE CT, WEIR DG, O'MOORE RR: Effects of an enteric anaerobic bacterial culture supernatant and deoxycholate on intestinal calcium absorption and disaccharidase activity, **770**
WALT RP. *See* HANNAN A, **1246**; MERKI HS, **148**
WANDELL JH. *See* RUNE SJ, **151**
WANI M, HISHON S: ECG record during changes in oesophageal pH, **127**
WARNES TW. *See* MCMAHON RFT, **484**
WASTELL C. *See* JOHNSON CD, **862**
WATANABE M. *See* HIBI T, **1371**
WATANABE N. *See* HIBI T, **1371**
WATSON AJM, ELLIOTT EJ, ROLSTON DDK, BORODO MM, FARTHING MJG, FAIRCLOUGH PD: Acetate absorption in the normal and secreting rat jejunum, **170**
WATSON BW. *See* COLSON DJ, **370**
WATT PCH. *See* COLLINS JSA, **858**
WEBB AK. *See* BILTON D, **236**
WECHSLER JG. *See* JANOWITZ P, **1407**
WEE A, KANG JY, HO MS, CHOONG HL, WU AYT, SUTHERLAND IH: Gastroduodenal mucosa in uraemia: endoscopic and histological correlation and prevalence of helicobacter-like organisms, **1093**
WEE A. *See also* KANG JY, **476**, **550**, **850**
WEGMAN EA, GANDEVIA SC, ANISS AM: Concordance between colonic myoelectrical signals recorded with intramuscular electrodes in the human rectosigmoid in vivo, **1289**
WEIR DG. *See* CAFFREY C, **663**; FEIGHERY C, **584**; WALSHE K, **770**
WETERMAN IT, BIEMOND I, PENA AS: Mortality and causes of death in Crohn's disease. Review of 50 years' experience in Leiden University Hospital, **1387**
WETERMAN IT. *See* APARICIO-PAGES MN, **1030**
WEYNAND B. *See* HAOT J, **840**
WHELAN A. *See* FEIGHERY C, **584**
WHELTON MJ. *See* O'MAHONY D, **717**
WHORWELL PJ. *See* MAXTON DG, **351**; PRIOR A, **458**, **896**
WIESNAGROTZKI S. *See* KISS A, **259**
WILD SR. *See* WILLIAMS AJK, **1082**
WILDER-SMITH C. *See* MERKI HS, **148**
WILKINSON M. *See* DIAMOND T, **82**
WILKINSON SP. *See* BATE CM, **968**
WILLEMS G. *See* TIELEMANS Y, **274**
WILLETTE M. *See* HAOT J, **282**
WILLIAMS A: Macrophage activity in inflammatory bowel disease *(Letter)*, **481**
WILLIAMS AJK, WILD SR, PALMER KR: Adult hepatic fibropoiycystic disease presenting as obstructive jaundice *(Case report)*, **1082**
WILLIAMS CB. *See* CHOY MY, **1365**; LENNARD-JONES JE, **800**
WILLIAMS EI. *See* JONES RH, **401**
WILLIAMS GT. *See* DE DOMBAL FT, **115**; SEYMOUR DG, **719**
WILLIAMS JG, HUGHES LE, HALLETT MB: Toxic oxygen metabolite production by circulating phagocytic cells in inflammatory bowel disease, **187**
WILLIAMS NS. *See* WALDRON DJ, **1284**
WILLIAMS R. *See* CUNDY TF, **337**
Williams, Roger, short biography of, **1084**
WILLIAMSON RCN. *See* GRACE PA, **571**
WILTGEN C. *See* TALLEY NJ, **77**
WINDELBORG B. *See* NOLTE H, **791**
WINGATE DL. *See* WALDRON DJ, **1284**
WIRTH S. *See* KELLER KM, **1156**
WISE LS. *See* TAKAHASI F, **1016**
WITZEL L. *See* MERKI HS, **148**
WOOD AJ. *See* DILL S, **1237**
WRIGHT NA. *See* THOMPSON EM, **406**
WRIGHT VA. *See* COLSON DJ, **370**
WU AYT. *See* WEE A, **1093**
WULFF HR. *See* RUNE SJ, **151**
WYATT JI. *See* HESSEY SJ, **134**
WYMAN JB, DENT J, HEDDLE R, DODDS WJ, TOOULI J, DOWNTON J: Control of belching by the lower oesophageal sphincter, **639**

XAVIER-NETO J, DOS SANTOS AA, ROLA FH: Acute hypervolaemia increases gastroduodenal resistance to the flow of liquid in the rat, **1006**

YAMAMOTO K. *See* SAKU T, **1250**
YAMAMOTO T. *See* OKADA M, **758**
YAO T. *See* OKADA M, **758**
YAP I. *See* KANG JY, **476**, **850**
YARRED LJ. *See* JEFFREY GP, **698**
YASAWI MI. *See* MOHAMED ARE, **439**
Yeast antibody in Crohn's disease, **536**
Yersinia enterocolitica, invasion of Peyer's patches by, involvement of M cells, **1011**
YOKOTA Y. *See* TATSUTA M, **973**
YOUNES M. *See* SCHOENBERG MH, **1138**
YOUNG A, LEVIN RJ: Diarrhoea of famine and malnutrition: investigations using a rat model. 1 Jejunal hypersecretion induced by starvation, **43**; 2 Ileal hypersecretion induced by starvation, **162**
YOUNG GP. *See* ALBERT V, **311**, **959**
YOUNG J. *See* FREEMAN TC, **1318**

ZANELLI G. *See* BJARNASON I, **777**
ZENTILIN P. *See* MELA GS, **1087**
ZIEGLER F, OLLIVIER JM, CYNOBER L, MASINI JP, COUDRAY-LUCAS C, LEVY E, GIBOUDEAU J: Efficacy of enteral nitrogen support in surgical patients: small peptides v non-degraded proteins, 1277
ZIJLSTRA FJ. *See* VAN DER HAM AC, **807**
Zinc: normal concentrations in acrodermatitis enteropathica *(Letter)*, **243**
status and hepatic functional reserve in liver disease, **694**
ZINSMEISTER AR. *See* KAMATH PS, **443**; TALLEY NJ, **54**, **77**
ZINZUVADIA SN. *See* ROLSTOB DDK, **1115**
ZIRONI G. *See* BOLONDI L, **1306**
ZOLLER A. *See* JANOWITZ P, **1407**
ZSELI J. *See* VIZI ES, **1046**

Owing to production difficulties the Abstract index will be published in Volume 32, January issue.